## PRIVATE COMPANY LIMITED BY SHARES

#### WRITTEN RESOLUTIONS

OF

#### **IMMUNOCORE LIMITED**

On 14 February 2020, the following special resolutions were duly passed as written resolutions of the Company pursuant to section 288 of the Companies Act 2006:

#### **SPECIAL RESOLUTIONS**

- 1. THAT each member of the Company hereby waives any rights of pre-emption conferred on that member by the articles of association of the Company or otherwise over the allotment of any shares in the Company in connection with the Series B Round.
- 2. THAT, with effect from and conditional on first closing of the Series B Round, the draft articles of association appended to this resolution at Annex I (with such minor amendments, additions, deletions or other modifications any director of the Company may approve) be adopted as the articles of association of the Company in substitution for, and to the exclusion of, the Company's existing articles of association.

For these purposes, the "Series B Round" means: (i) the proposed issue and allotment of new Series B Shares of £0.0001 each in the capital of the Company for aggregate consideration of an amount in pounds sterling equal to up to \$300,000,000 on or before 30 September 2020 (including the issue and allotment of Series B Shares in more than one instalment and the issue and allotment of Series B Shares under associated contractual arrangements); and (ii) the issue of ordinary shares in the capital of the Company as may be required by, and in accordance with, the articles of association of the Company.

Secretary

[ MH-pusaron

\*A9Ø9FLQH\*
A14 06/03/2020 #122
COMPANIES HOUSE

#### PRIVATE COMPANY LIMITED BY SHARES

# WRITTEN RESOLUTIONS

OF

#### **IMMUNOCORE LIMITED**

On 14 February 2020, the following special resolutions were duly passed as written resolutions of the Company pursuant to section 288 of the Companies Act 2006:

#### **SPECIAL RESOLUTIONS**

- 1. THAT in accordance with section 551 of the Act, the directors of the Company (or a duly constituted committee of the directors) (the "Directors") be generally and unconditionally authorised to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company ("Rights") to The Bill & Melinda Gates Foundation (the "Foundation"), or any assignee or transferee of any Rights or agreement to grant Rights to the Foundation, up to an nominal amount of £16, provided that this authority shall, unless sooner renewed, varied or revoked by the Company, expire on the date that is five years from the date of passing this of this Resolution.
- 2. THAT in accordance with section 551 of the Act, the Directors be unconditionally authorised to allot Ordinary Shares of £0.0001 each in the capital of the Company up to an aggregate nominal amount of £1. Unless renewed, varied or revoked by the Company, this authority shall expire on the date that is five years from the date of passing of this Resolution.

Secretary

LMHyworm.

## **PRIVATE COMPANY LIMITED BY SHARES**

## WRITTEN RESOLUTIONS

OF

## **IMMUNOCORE LIMITED**

On 14 February 2020, the following special resolutions were duly passed as written resolutions of the Company pursuant to section 288 of the Companies Act 2006:

## **SPECIAL RESOLUTIONS**

1. THAT each member of the Company hereby waives any rights of pre-emption conferred on that member by the articles of association of the Company or otherwise over the allotment of any shares in the Company in connection with the Gates Investment.

For these purposes, the "Gates Investment" means (i) the proposed issue and allotment of shares in the Company or the granting of Rights to the Foundation, or any assignee or transferee of any Rights or agreements to grant Rights to the Foundation, up to a nominal amount of £16, on or before the date that is five years from the date of passing of this Resolution; and (ii) the issue of ordinary shares in the capital of the Company as may be required by, and in accordance with, the articles of association of the Company.

Secretary

LMHerwort->

# **PRIVATE COMPANY LIMITED BY SHARES**

#### WRITTEN RESOLUTIONS

OF

#### **IMMUNOCORE LIMITED**

On 14 February 2020, the following special resolutions were duly passed as written resolutions of the Company pursuant to section 288 of the Companies Act 2006:

#### SPECIAL RESOLUTIONS

- 1. THAT in accordance with section 551 of the Act, the directors of the Company (or a duly constituted committee of the directors) (the "Directors") be generally and unconditionally authorised to allot Series B Shares of £0.0001 each in the capital of the Company (each having the respective rights and subject to the respective restrictions set out in the articles of association of the Company adopted pursuant to a special resolution passed on or around the date of this resolution) up to an aggregate nominal amount of £66 in connection with the Series B Round. Unless renewed, varied or revoked by the Company, this authority shall expire on 30 September 2020.
- THAT in accordance with section 551 of the Act, the Directors be unconditionally authorised to allot Ordinary Shares of £0.0001 each in the capital of the Company up to an aggregate nominal amount of £7. Unless renewed, varied or revoked by the Company, this authority shall expire on 30 September 2020.

For these purposes, the "Series B Round" means: (i) the proposed issue and allotment of new Series B Shares of £0.0001 each in the capital of the Company for aggregate consideration of an amount in pounds sterling equal to up to \$300,000,000 on or before 30 September 2020 (including the issue and allotment of Series B Shares in more than one instalment and the issue and allotment of Series B Shares under associated contractual arrangements); and (ii) the issue of ordinary shares in the capital of the Company as may be required by, and in accordance with, the articles of association of the Company.

Secretary

LM Hepum?

# THE COMPANIES ACT 2006 COMPANY LIMITED BY SHARES NEW ARTICLES OF ASSOCIATION

of

# **IMMUNOCORE LIMITED**

(Adopted by a special resolution effective on 14 February 2020)

# CONTENTS

1.	Introduction	1
2.	Definitions	2
3.	Share capital	13
4.	Dividends	14
<b>5</b> .	Liquidation preference	15
6.	Exit provisions	17
7.	Foundation share buyback or foundation share sale	18
8.	Votes in general meeting and written resolutions	18
9.	Consolidation of Shares	20
10.	Conversion of Series A Shares	20
11.	Anti-Dilution protection	22
12.	Conversion of G Ordinary Shares	23
13.	Variation of rights	25
14.	Allotment of new shares or other securities: pre-emption	25
15.	Transfers of Shares — general	29
16.	Permitted Transfers	31
17.	Transfers of Shares subject to pre-emption rights	33
18.	Valuation of Shares	38
19.	Compulsory transfers — general	39
20.	Mandatory offer on a change of control	40
21.	Drag-along	41
22.	General meetings	43
23.	Proxies	44
24.	Directors' borrowing powers	45
25.	Alternate Directors	45
26.	Number of Directors	46
27.	Appointment of Directors	46
28.	Disqualification of Directors	49
29.	Proceedings of Directors	49
30.	Directors' interests	50
31.	Notices	54
32.	Indemnities and insurance	56
33.	Data Protection	57
34.	Secretary	58
35.	Lien	58
36.	Call Notices	59
37.	Forfeiture of Shares	61
38.	Surrender of Shares	63
39.	Authority to capitalise and appropriation of capitalised sums	63
40.	Series B Shares	64
41.	Share Sale	68
42	IPO	68

## **COMPANY LIMITED BY SHARES**

#### **NEW ARTICLES OF ASSOCIATION**

#### OF IMMUNOCORE LIMITED

(Adopted by a special resolution effective on 14 February 2020)

# 1. INTRODUCTION

- 1.1 The model Articles for private companies limited by shares contained or incorporated in Schedule 1 to the Companies (Model Articles) Regulations 2008 (SI 2008/3229) as amended prior to the date of adoption of these Articles (the **Model Articles**) shall apply to the Company, save insofar as they are varied or excluded by, or are inconsistent with, the following Articles.
- 1.2 In these Articles and the Model Articles any reference to any statutory provision shall be deemed to include a reference to each and every statutory amendment, modification, reenactment and extension thereof for the time being in force.

# 1.3 In these Articles:

- (a) Article headings are used for convenience only and shall not affect the construction or interpretation of these Articles;
- (b) words denoting the singular include the plural and vice versa and reference to one gender includes the other gender and neuter and vice versa;
- (c) Articles 8(2), 9(4), 10(3), 11(2), 13, 14, 17(2), 17(3), 19, 21, 26(5), 27, 28, 29, 30(5) to (7) (inclusive), 44(4), 51, 52 and 53 of the Model Articles shall not apply to the Company;
- reference to issued Shares of any class shall exclude any Shares of that class held as Treasury Shares from time to time, unless stated otherwise; and
- (e) reference to the **holders** of Shares or a class of Share shall exclude the Company holding Treasury Shares from time to time, unless stated otherwise.
- In respect of any actions or matters requiring or seeking the acceptance, approval, agreement, consent or words having similar effect of an Investor Director under these Articles, if at any time an Investor Director has not been appointed or an Investor Director declares in writing to the Company that he or she considers that providing such consent gives rise or may give rise to a conflict of interest to his duties as a Director, such action or matter shall require the prior written consent of the appointing Investor(s).
- 1.5 Where there is reference to Series A Shares or Series B Shares under these Articles, this reference shall be treated, where appropriate in the context, on an as converted basis.

# 2. **DEFINITIONS**

In these Articles the following words and expressions shall have the following meanings:

Act means the Companies Act 2006 (as amended from time to time);

Acting in Concert has the meaning given to it in The City Code on Takeovers and Mergers published by the Panel on Takeovers and Mergers (as amended from time to time);

Actions shall have the meaning given in Article 6.3;

Anti-Dilution Shares shall have the meaning given in Article 11.1;

Applying Shareholder has the meaning given in Article 17.6.4(b);

Appointing Series B Investor has the meaning given in Article 27.1(d);

Appointor has the meaning given in Article 25.1;

Asset Sale means the disposal by the Company of all or substantially all of its undertaking and assets (where disposal may include, without limitation, the grant by the Company of an exclusive licence of intellectual property not entered into in the ordinary course of business);

Associate in relation to any person means:

- (a) any person who is an associate of that person and the question of whether a person is an associate of another is to be determined in accordance with section 435 of the Insolvency Act 1986; or (whether or not an associate as so determined)
- (b) any Member of the same Group; or
- (c) any Member Of The Same Fund Group;

Auditors means the auditors of the Company from time to time;

**Available Profits** means profits available for distribution within the meaning of part 23 of the Act:

**Board** means the board of Directors and any committee of the board constituted for the purpose of taking any action or decision contemplated by these Articles;

Board Review has the meaning given in Article 27.5;

Bonus Issue or Reorganisation means any return of capital, bonus issue of shares or other securities of the Company by way of capitalisation of profits or reserves (other than a capitalisation issue in substitution for or as an alternative to a cash dividend which is made available to the Series A Shareholders or Series B Shareholders) or any consolidation or sub-division or redenomination or any repurchase or redemption of shares (other than Series A Shares or Series B Shares) or any variation in the subscription price or conversion rate applicable to any other

outstanding shares of the Company in each case other than shares issued as a result of the events set out in Article 14.9;

**Business Day** means a day on which English clearing banks are ordinarily open for the transaction of normal banking business in the City of London (other than a Saturday or Sunday);

Called Shareholder has the meaning given in Article 21.1;

**Civil Partner** means in relation to a Shareholder, a civil partner (as defined in the Civil Partnership Act 2004) of the Shareholder;

**Code** means the United States Internal Revenue Code of 1986, as amended, and the regulations thereunder;

Company means Immunocore Limited;

Company G Share Conversion Notice has the meaning given in Article 12.2;

Company's Lien has the meaning given in Article 35.1;

Conditions has the meaning given in Article 10.2;

Controlling Interest means an interest in shares giving to the holder or holders control of the Company within the meaning of section 1124 of the CTA 2010;

**Conversion Date** has the meanings given in Article 10.2 and Article 10.3(a) (as applicable);

Conversion Ratio has the meaning given in Article 10.6;

CTA 2010 means the Corporation Tax Act 2010;

Date of Adoption means 14 February 2020;

**Deferred Shares** means the deferred shares of £0.0001 each in the capital of the Company from time to time;

**Director(s)** means a director or directors of the Company from time to time;

Drag Along Option has the meaning given in Article 21.1;

Drag Completion Date has the meaning given in Article 21.5;

Drag Consideration has the meaning given in Article 21.4;

**Drag Documents** has the meaning given in Article 21.5;

Drag Purchaser has the meaning given in Article 21.1;

electronic address has the same meaning as in section 333 of the Act;

**electronic form** and **electronic means** have the same meaning as in section 1168 of the Act;

**Eligible Director** means a Director who would be entitled to vote on a matter had it been proposed as a resolution at a meeting of the Directors;

**Employee** means an individual who is employed by, or who provides consultancy services to, or is a director (excluding any Director appointed under Articles 26.1(a) to 26.1(d)) of the Company or any member of the Group;

**Employee Nominee** means any person, including a body corporate, (not being the trustee of an employee benefit trust) approved by the Board who holds Shares on behalf of an Employee or former Employee;

**Encumbrance** means any mortgage, charge, security, interest, lien, pledge, assignment by way of security, equity, claim, right of pre-emption, option, covenant, restriction, reservation, lease, trust, order, decree, judgment, title defect (including without limitation any retention of title claim), conflicting claim of ownership or any other encumbrance of any nature whatsoever (whether or not perfected other than liens arising by operation of law);

**Equity Securities** has the meaning given in sections 560(1) to (3) inclusive of the Act and for the avoidance of doubt an allotment of Equity Securities includes a transfer of shares which immediately before such transfer were held by the Company as Treasury Shares;

**Equity Shares** means the Ordinary Shares and the Series A Shares and the Series B Shares;

**Exercising Investor** means any Investor who exercises its rights to acquire Anti-Dilution Shares in accordance with Article 11.1;

Exit means a Share Sale or an Asset Sale;

Expert Valuer is as determined in accordance with Article 18.2;

Fair Value is as determined in accordance with Article 18;

Family Trust means as regards any particular individual member or deceased or former individual member, trusts (whether arising under a settlement, declaration of trust or other instrument by whomsoever or wheresoever made or under a testamentary disposition or on an intestacy) under which no immediate beneficial interest in any of the shares in question is for the time being vested in any person other than the individual and/or Privileged Relations of that individual, and so that for this purpose a person shall be considered to be beneficially interested in a share if such share or the income thereof is liable to be transferred or paid or applied or appointed to or for the benefit of such person or any voting or other rights attaching thereto are exercisable by or as directed by such person pursuant to the terms of the relevant trusts or in consequence of an exercise of a power or discretion conferred thereby on any person or persons;

Financial Year has the meaning set out in section 390 of the Act;

First Offer Period has the meaning given in Article 17.6.2(a);

First Subscription Period has the meaning given in Article 14.5(a);

**Foundation** means the Bill & Melinda Gates Foundation or any Permitted Transferee of the Foundation;

Foundation Share Buyback means an off-market share buyback by the Company of all the Foundation Shares at the Transfer Value in accordance with Chapter 4 of Part 18 of the Act, whether out of the distributable profits of the Company at such time in accordance with Section 692(2) of the Act or, to the extent that insufficient distributable profits exist at such time, out of capital in accordance with Chapter 5 of Part 18 of the Act;

Foundation Shares means all Shares held by the Foundation;

**Foundation Share Sale** means the sale to one or more persons (which, for the avoidance of doubt, may include any Shareholder) of the Foundation Shares at the Transfer Value;

Fractional Holders has the meaning given in Article 10.10 and 12.5;

**Fund Manager** means a person whose principal business is to make, manage or advise upon investments in securities;

**G Shares** means together the G1 Shares, G2 Shares, G3 Shares, G4 Shares, G5 Shares, G6 Shares, G7 Shares, G8 Shares, G9 Shares and G10 Shares from time to time;

**G Shareholders** means the holders from time to time of the G Shares (but excludes the Company holding Treasury Shares);

G Share Conversion Notice has the meaning given in Article 12.2;

**G Share Subscription Agreement** means an agreement between the Company and an Employee, in the form approved by the Board, under the terms of which the Employee subscribes for G Shares;

**G1 Hurdle Amount** means the amount per G1 Share determined by the Directors, prior to the issue of any G1 Ordinary Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G1 Hurdle Amount;

**G1 Shares** means the G1 shares of £0.0001 each in the capital of the Company from time to time;

**G2 Hurdle Amount** means the amount per G2 Share determined by the Directors, prior to the issue of any G2 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G2 Hurdle Amount;

**G2** Shares means the G2 shares of £0.0001 each in the capital of the Company from time to time:

**G3 Hurdle Amount** means the amount per G3 Share determined by the Directors, prior to the issue of any G3 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G3 Hurdle Amount;

**G3 Shares** means the G3 shares of £0.0001 each in the capital of the Company from time to time:

- **G4 Hurdle Amount** means the amount per G4 Share determined by the Directors, prior to the issue of any G4 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G4 Hurdle Amount;
- **G4 Shares** means the G4 shares of £0.0001 each in the capital of the Company from time to time;
- **G5 Hurdle Amount** means the amount per G5 Share determined by the Directors, prior to the issue of any G5 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G5 Hurdle Amount;
- **G5 Shares** means the G5 shares of £0.0001 each in the capital of the Company from time to time;
- **G6 Hurdle Amount** means the amount per G6 Share determined by the Directors, prior to the issue of any G6 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G6 Hurdle Amount;
- **G6 Shares** means the G6 shares of £0.0001 each in the capital of the Company from time to time;
- **G7 Hurdle Amount** means the amount per G7 Share determined by the Directors, prior to the issue of any G7 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G7 Hurdle Amount;
- **G7 Shares** means the G7 shares of £0.0001 each in the capital of the Company from time to time:
- **G8 Hurdle Amount** means the amount per G8 Share determined by the Directors, prior to the issue of any G8 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G8 Hurdle Amount;
- **G8 Shares** means the G8 shares of £0.0001 each in the capital of the Company from time to time;
- **G9 Hurdle Amount** means the amount per G9 Share determined by the Directors, prior to the issue of any G9 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G9 Hurdle Amount;
- **G9 Shares** means the G9 shares of £0.0001 each in the capital of the Company from time to time:
- **G10 Hurdle Amount** means the amount per G10 Share determined by the Directors, prior to the issue of any G10 Shares or as amended pursuant to Articles 13.3 or 13.4, as being the G10 Hurdle Amount;
- **G10 Shares** means the G10 shares of £0.0001 each in the capital of the Company from time to time;
- GA Investor Director has the meaning given in Article 27.1(c);
- **General Atlantic** means GA IMC Holding, L.P., acting by its general partner GA IMC Holding, Ltd;

**Group** means the Company and its Subsidiary Undertaking(s) (if any) from time to time and **Group Company** shall be construed accordingly;

hard copy form has the same meaning as in section 1168 of the Act;

Holding Company means a newly formed holding company in which the shareholdings match that of the Company (except Treasury Shares) immediately prior to the transfer of the issued share capital of the Company to such holding company;

**Hurdle Amount** means the hurdle amount applicable to the relevant class of G Share, being together the G1 Hurdle Amount, the G2 Hurdle Amount, the G3 Hurdle Amount, the G4 Hurdle Amount, the G5 Hurdle Amount, the G6 Hurdle Amount, the G7 Hurdle Amount, the G8 Hurdle Amount, the G9 Hurdle Amount and the G10 Hurdle Amount:

**Initial GA Holding** means the number of Series B Shares held by General Atlantic as at the Date of Adoption;

**Investment Fund** means a fund, partnership, company, mandate syndicate or other entity whose business is managed or advised (in an investment advisory capacity) by a Fund Manager;

**Investment Round** means (i) the Series B Round; and (ii) the issue and allotment of any new class of Shares in the capital of the Company (including the issue and allotment of Shares in more than one instalment as part of a single funding round) from the Date of Adoption;

**Investor Directors** means the Series A Investor Director, Lilly Director, Series B Investor Director and the GA Investor Directors (if and to the extent appointed pursuant to Article 27.1) or any of them as the context requires;

**Investors** means each of the Series A Shareholders and Series B Shareholders and their Permitted Transferees;

**IPO** means the admission of all or any of the IPO Shares or securities representing those IPO Shares (including, without limitation, depositary interests, American depositary receipts, American depositary shares and/or other instruments) on the New York Stock Exchange, NASDAQ or on the Official List of the United Kingdom Listing Authority or on the AIM Market operated by the London Stock Exchange Plc or any other Recognised Investment Exchange (as defined in section 285 of the Financial Services and Markets Act 2000);

**IPO Shares** means shares (of any class) in the capital of the Company or any Holding Company or Subsidiary Undertaking of the Company (as applicable) holding, directly or indirectly, all or substantially all of the assets of the Company's Group;

ITEPA means Income Tax (Earnings and Pensions) Act 2003;

**Issue Price** means the price in pounds sterling at which the relevant Share is issued, including any premium, provided that:

- (a) the Issue Price per Series A Share shall be the Series A Price;
- (b) the Issue Price per Series B Share shall be the Series B Price;
- (c) the Issue Price of any Anti-Dilution Shares shall be deemed to be the Issue Price of those Shares held by a Shareholder which carried the right to have issued such Anti-Dilution Shares; and
- (d) the Issue Price of any Series B Anti-Dilution Shares shall be deemed to be the Issue Price of those Shares held by a Shareholder which carried the right to have issued such Series B Anti-Dilution Shares;

Lien Enforcement Notice has the meaning given in Article 35.3;

**Lilly** means Eli Lilly S.A., a company registered in the commercial register of the Canton of Geneva under number CHE-103.898.717, having its registered seat at Chemin des Coquelicots 16, 1214 Vernier;

Lilly Director has the meaning given in Article 27.1(b);

- a Member Of The Same Fund Group means if the Shareholder is an Investment Fund or is a nominee of that Investment Fund:
- (a) any participant or partner in or member of any such Investment Fund or the holders of any unit trust which is a participant or partner in or member of any Investment Fund (but only in connection with the dissolution of the Investment Fund or any distribution of assets of the Investment Fund pursuant to the operation of the Investment Fund in the ordinary course of business);
- (b) any Investment Fund managed or advised by that Fund Manager or another member of the Investment Fund's Group;
- (c) any Parent Undertaking or Subsidiary Undertaking of the Investment Fund or Fund Manager, or any Subsidiary Undertaking of any Parent Undertaking of the Investment Fund or Fund Manager; or
- (d) any trustee, nominee or custodian of such Investment Fund and vice versa;
- a Member of the same Group means as regards any company, a company which is from time to time a Parent Undertaking or a Subsidiary Undertaking of that company or a Subsidiary Undertaking of any such Parent Undertaking;

NASDAQ means the NASDAQ Stock Market of the NASDAQ OMX Group Inc.;

**New Securities** means any shares or other securities convertible into, or carrying the right to subscribe for, those shares issued by the Company after the Date of Adoption (other than shares or securities issued as a result of the events set out in Article 14.9, excluding the event set out in Article 14.9(c)) excluding for the avoidance of doubt any Treasury Shares transferred by the Company after the Date of Adoption;

Offer has the meaning set out in Article 20.2;

Offer Period has the meaning set out in Article 20.3;

**Ordinary Shareholders** means the holders from time to time of the Ordinary Shares (but excludes the Company holding Treasury Shares);

**Ordinary Shares** means the ordinary shares of £0.0001 each in the capital of the Company from time to time;

Original Shareholder has the meaning set out in Article 16.1;

Parent Undertaking has the meaning set out in section 1162 of the Act;

Participating G Share and Participating G Shareholder have the meanings set out in Article 5.2.1;

**Permitted Transfer** means a transfer of Shares that is permitted in accordance with Article 16;

#### Permitted Transferee means:

- (a) in relation to a Shareholder who is an individual, any of his Privileged Relations, Trustees or Qualifying Companies;
- (b) in relation to a Shareholder which is an undertaking (as defined in section 1161(1) of the Act), means any Member of the same Group;
- (c) in relation to Isis College Fund, any members of the Isis College Fund;
- in relation to a Shareholder which is an Investment Fund, means any Member Of The Same Fund Group;
- (e) in relation to an Investor:
  - (i) any Member of the same Group;
  - (ii) any Member of The Same Fund Group;
  - (iii) subject to Article 16.1, any other Investor; and
  - (iv) any nominee of that Investor;
- (f) in relation to the Foundation:
  - (i) any successor charitable organisation of the Foundation from time to time that is a tax-exempt organisation as described in Section 501(c)(3) of the Code; and
  - (ii) any tax-exempt organisation as described in Section 501(c)(3) of the Code controlled by one or more trustees of the Foundation;

Preference Amount has the meaning given to it in Article 5.1.2;

**Preference Dividends** means the Series A Preference Dividend and the Series B Preference Dividend;

**Privileged Relation** in relation to a Shareholder who is an individual member or deceased or former member means a spouse, Civil Partner, child or grandchild (including step or adopted or illegitimate child and their issue);

**Proceeds of Sale** means the consideration payable (including any deferred consideration) whether in cash or otherwise to those Shareholders selling Shares under a Share Sale less any fees, costs and expenses payable in respect of such Share Sale;

Proposed Exit has the meaning given in Article 6.3;

**Proposed Purchaser** means a proposed purchaser who at the relevant time has made an offer on arm's length terms;

Proposed Sale Date has the meaning given in Article 20.3;

Proposed Sale Notice has the meaning given in Article 20.3;

Proposed Sale Shares has the meaning given in Article 20.3;

**Proposed Seller** means any person proposing to transfer any shares in the capital of the Company;

Proposed Transfer has the meaning given in Article 20.1;

Qualifying Company means a company in which a Shareholder or Trustee(s) holds the entire issued share capital and over which that Shareholder or Trustee(s) exercises control (within the meaning of section 1124 of the CTA 2010);

Qualifying IPO means an IPO in which: (a) the net aggregate subscription amount in respect of new IPO Shares issued at the time of the IPO is not less than \$150,000,000; and (b) the net price per new IPO Share is equal to at least 125% of the Series B Price;

Qualifying Person has the meaning given in section 318(3) of the Act;

Relevant Interest has the meaning set out in Article 30.5;

Sale Shares has the meaning set out in Article 17.2(a);

Second Offer Period has the meaning given in Article 17.6.2(b);

Second Subscription Period has the meaning given in Article 14.5(b);

**Secondary Market Arrangements** means any such arrangements as the Directors may put in place from time to time for the purpose of facilitating sales of Shares by Employees or former Employees;

Seller has the meaning set out in Article 17.2;

Selling Shareholders has the meaning given in Article 21.1;

Series A Applying Shareholders has the meaning given in Article 17.6.4(a);

Series A Investor Director has the meaning given in Article 27.1(a);

**Series A Majority** means the holders of at least 65 per cent. of the Series A Shares from time to time;

**Series A Majority Consent** means the prior written consent of the Series A Majority;

Series A Preference Dividend has the meaning given in Article 4.2(b);

Series A Price means £120.93 (if applicable, adjusted as referred to in Article 11.3);

**Series A Shareholders** means the holders of the Series A Shares (but excludes the Company holding Treasury Shares);

**Series A Shares** means the series A shares of £0.0001 each in the capital of the Company from time to time;

Series B Anti-Dilution Shares has the meaning given in Article 40.12;

Series B Applying Shareholders has the meaning given in Article 17.6.4(a);

Series B Conditions has the meaning given in Article 40.2;

Series B Conversion Date has the meaning given in Article 40.5;

Series B Conversion Ratio has the meaning given in Article 40.6;

Series B Exercising Investor has the meaning given in Article 40.12;

Series B Fractional Holder has the meaning given in Article 40.10;

Series B Investor Director has the meaning given in Article 27.1(d);

**Series B Majority** means the holders of at least 65 per cent. of the Series B Shares from time to time;

**Series B Majority Consent** means the prior written consent of the Series B Majority;

Series B Preference Amount has the meaning given in Article 5.1.1;

Series B Preference Dividend has the meaning given in Article 4.2(a);

Series B Price means £96.19 (if applicable, adjusted as referred to in Article 40.14);

Series B Qualifying Issue has the meaning given in Article 40.12;

**Series B Round** means the allotment and issue of new Series B Shares on the Date of Adoption and pursuant to all Subsequent Closings;

Series B Shareholders means the holders of the Series B Shares;

**Series B Shares** means the series B shares of £0.0001 each in the capital of the Company from time to time;

**Shareholder** means any holder of any Shares (but excludes the Company holding Treasury Shares);

Shareholder G Share Conversion Notice has the meaning given in Article 12.1;

Share Option Plan(s) means the share option plan(s) of the Company;

Shares means shares (of any class) in the capital of the Company;

Share Sale means the sale of (or the grant of a right to acquire or to dispose of) any of the shares in the capital of the Company (in one transaction or as a series of transactions) which will result in the purchaser of those shares (or grantee of that right) and persons Acting in Concert with him together acquiring a Controlling Interest in the Company, except where following completion of the sale the shareholders and the proportion of shares held by each of them are the same as the shareholders and their shareholdings in the Company immediately prior to the sale:

Subscribing Series A Shareholders has the meaning given in Article 14.6(a);

Subscribing Series B Shareholders has the meaning given in Article 14.6(a);

Subscribing Shareholders has the meaning given in Article 14.6(b);

**Subsequent Closing** means the issue of up to 660,000 new Series B Shares (in aggregate) at any time or times from the Date of Adoption of these Articles until (and including) 30 September 2020;

**Subsidiary** and **Subsidiary Undertaking** have the respective meanings set out in sections 1159 and 1162 of the Act;

Surplus Assets has the meaning given in Article 5;

Third Offer Period has the meaning given in Article 17.6.2(c);

Third Subscription Period has the meaning given in Article 14.5(c);

Transfer Notice shall have the meaning given in Article 17.2;

Transfer Price shall have the meaning given in Article 17.2;

**Transfer Value** means the greater of (i) the original issue price attributable to the Foundation Shares plus interest at 2 per cent. per annum (compounded annually over the period from the date of issue of the relevant Foundation Shares to the date of completion of the Foundation Share Buyback or the Foundation Share Sale, as the case may be); and (ii) the Fair Value of the Foundation Shares calculated in accordance with the provisions of Article 18 (Valuation of Shares) (as if the Foundation Shares were Sale Shares for the purposes of such Article);

**Treasury Shares** means shares in the capital of the Company held by the Company as treasury shares from time to time within the meaning set out in section 724(5) of the Act;

**Trustees** in relation to a Shareholder means the trustee or the trustees of a Family Trust;

WEIF means the CF Woodford Equity Income Fund;

WIM means Woodford Investment Management LLP; and

WPCT means Woodford Patient Capital Trust plc.

# 3. SHARE CAPITAL

- 3.1 In these Articles, unless the context requires otherwise, references to shares of a particular class shall include shares allotted and/or issued after the Date of Adoption and ranking pari passu in all respects (or in all respects except only as to the date from which those shares rank for dividend) with the shares of the relevant class then in issue.
- 3.2 Except as otherwise provided in these Articles, the Series A Shares, Series B Shares and the Ordinary Shares shall rank pari passu in all respects but shall constitute separate classes of shares. The G Shares and Deferred Shares carry only the rights expressly set out in these Articles.
- 3.3 The words "and the directors may determine the terms, conditions and manner of redemption of any such shares" shall be deleted from Article 22(2) of the Model Articles.
- 3.4 Without prejudice to the Company's power to purchase Shares under any other provision of the Act, subject to Series A Majority Consent and Series B Majority Consent, the Company may purchase Shares out of capital in accordance with and to the extent permitted by section 692(1ZA) of the Act.
- 3.5 The allotment or issue of Deferred Shares or the conversion or re-designation of shares into Deferred Shares shall be deemed to confer irrevocable authority on the Company at any time after their allotment, issue, conversion or re-designation, without obtaining the sanction of their holder(s), to:
  - appoint any person to execute any transfer (or any agreement to transfer) such Deferred Shares to such person(s) as the Company may determine (as nominee or custodian thereof or otherwise); and/or
  - (b) give, on behalf of such holder, consent to the cancellation of such Deferred Shares; and/or
  - (c) purchase such Deferred Shares in accordance with the Act,

in any such case (i) for a price being not more than an aggregate sum of one penny for all the Deferred Shares registered in the name of such holder(s) and (ii) with the Company having authority pending such transfer, cancellation and/or purchase to retain the certificates (if any) in respect thereof.

- 3.6 Paragraph (c) of Article 24(2) of the Model Articles shall be amended by the replacement of the words "that the shares are fully paid; and" with the words "the amount paid up on them; and".
- 3.7 In Article 25(2) of the Model Articles, the words "payment of a reasonable fee as the directors decide" in paragraph (c) shall be deleted and replaced by the words "payment of the expenses reasonably incurred by the Company in investigating evidence as the directors may determine".
- 3.8 For the avoidance of doubt, the Company shall not exercise any right in respect of any Treasury Shares, including without limitation any right to:

- (a) receive notice of or to attend or vote at any general meeting of the Company;
- (b) receive or vote on any proposed written resolution; and
- (c) receive a dividend or other distribution, save as otherwise permitted by section 726(4) of the Act.

# 4. DIVIDENDS

- 4.1 In respect of any Financial Year, the Company's Available Profits will be applied as set out in this Article 4.
- 4.2 The Company will, without any need for a resolution of the Company but with the approval of the Board in its sole discretion and before application of any profits to reserve or for any other purpose, pay:
  - (a) first (and in priority to any other classes of Shares), to the Series B Shareholders a fixed non-cumulative cash preferential dividend in respect of each Series B Share held by them at the annual rate of 8 per cent. of the Series B Price per Share (the Series B Preference Dividend) and to be paid to the person registered as its holder on the relevant date; and
  - (b) second (and in priority to any other classes of Shares, save for the Series B Shares), to the Series A Shareholders a fixed non-cumulative cash preferential dividend in respect of each Series A Share held by them at the annual rate of 8 per cent. of the Series A Price per Share (the Series A Preference Dividend) and to be paid to the person registered as its holder on the relevant date.
- 4.3 Any Available Profits which the Company may determine to distribute in respect of any Financial Year (after payment of the Preference Dividends in accordance with Article 4.2) will be distributed among the holders of the Equity Shares (pari passu as if the Equity Shares constituted one class of share) pro rata to their respective holdings of Equity Shares.
- 4.4 Subject to the Act and these Articles, the Board may, pay in respect of the Equity Shares (pari passu as if the Equity Shares constituted one class of share) interim dividends if justified by the Available Profits taking into account the requirement to pay the Preference Dividends in respect of the relevant period.
- 4.5 Every dividend shall accrue on a daily basis assuming a 365 day year. All dividends are expressed net and shall be paid in cash.
- 4.6 If there are nil paid or partly paid share(s), any holder of such share(s) shall only be entitled, in case of any dividend, to be paid an amount equal to the amount of the dividend multiplied by the percentage of the amount that is paid up (if any) on such share(s) during any portion or portions of the period in respect of which a dividend is paid.
- 4.7 A capitalised sum which was appropriated from profits available for distribution (which are not required for the Preference Dividends) may be applied in or towards

paying up any sums unpaid on existing Shares held by the persons entitled to such capitalised sum.

- 4.8 lf:
  - (a) a Share is subject to the Company's Lien; and
  - (b) the Directors are entitled to issue a Lien Enforcement Notice in respect of it,

they may, instead of issuing a Lien Enforcement Notice, deduct from any dividend or other sum payable in respect of the Share any sum of money which is payable to the Company by the holder of that Share to the extent that they are entitled to require payment under a Lien Enforcement Notice. Money so deducted shall be used to pay any of the sums payable in respect of that Share and/or used to discharge any other indebtedness owing from the holder of that Share to the Company (as the Board may decide). The Company shall notify the distribution recipient in writing of:

- (i) the fact and sum of any such deduction;
- (ii) any non-payment of a dividend or other sum payable in respect of a Share resulting from any such deduction; and
- (iii) how the money deducted has been applied.
- 4.9 Article 31(1) of the Model Articles shall be amended by:
  - (a) the replacement of the words "either in writing or as the directors may otherwise decide" at the end of paragraphs (a), (b) and (c) of that Article 31(1) with the words "in writing"; and
  - (b) the replacement of the words "either in writing or by such other means as the directors decide" from the end of paragraph (d) of that Article 31(1) with the words "in writing".
- 4.10 For the avoidance of doubt, save pursuant to Article 5 or Article 6.2, the G Shares and the Deferred Shares carry no rights to receive any dividend or other distribution.

# 5. LIQUIDATION PREFERENCE

- 5.1 Subject to Article 10.1 and Article 40.1, on a distribution of assets on a liquidation or a return of capital (other than a conversion, redemption or purchase of Shares or a dissolution on an Asset Sale) the surplus assets of the Company remaining after payment of its liabilities (**Surplus Assets**) shall be applied (to the extent that the Company is lawfully permitted to do so):
- 5.1.1 first in paying to each of the Series B Shareholders, in priority to any other classes of Shares, the Issue Price per Series B Share held by them, together with any declared but unpaid dividend (the Series B Preference Amount) (provided that if there are insufficient surplus assets to pay the amounts per share equal to the Series B Preference Amount, the remaining surplus assets shall be distributed to the Series B Shareholders pro rata to their respective holdings of Series B Shares);

- 5.1.2 second in paying to each of the Series A Shareholders, in priority to any other classes of Shares (save for the Series B Shares), the Issue Price per Series A Share held by them, together with any declared but unpaid dividend (the **Preference Amount**) (provided that if there are insufficient surplus assets to pay the amounts per share equal to the Preference Amount, the remaining surplus assets shall be distributed to the Series A Shareholders pro rata to their respective holdings of Series A Shares); and
- 5.1.3 subject to Article 5.3, any balance of the Surplus Assets will be distributed in accordance with the provisions of this Article 5.1.3:
  - (a) first, the balance of the Surplus Assets will be distributed among the holders of the Ordinary Shares, pro rata to the number of Ordinary Shares held, until either:
    - each Ordinary Shareholder has received an amount per Ordinary Share equal to the Hurdle Amount of the most senior class of G Share then in issue; or
    - (ii) all the Surplus Assets have been distributed; and
  - (b) then, any balance of the Surplus Assets will be distributed among the holders of the Ordinary Shares and the Participating G Shares pro rata to the number of Ordinary Shares and Participating G Shares held by them, until either:
    - each Ordinary Shareholder has received in aggregate (taking into account any previous distributions under this Article 5.1.3) an amount per Ordinary Share equal to the Hurdle Amount of the next most senior class of G Share then in issue; or
    - (ii) all the Surplus Assets have been distributed; and
  - (c) then any balance of the Surplus Assets will be distributed in a sequential series of distributions in the same manner to the Ordinary Shareholders and Participating G Shareholders pro rata to the number of Ordinary Shares and Participating G Shares held by them (until in relation to each sequential distribution each Ordinary Shareholder has received in aggregate (taking into account any previous distributions under this Article 5.1.3) an amount per Ordinary Share equal to the Hurdle Amount of the next most senior class of G Share then in issue) until either
    - (i) all the Surplus Assets have been distributed; or
    - (ii) each Ordinary Shareholder has received an amount per Ordinary Share equal to the Hurdle Amount of the most junior class of G Share then in issue, when any balance of the Surplus Assets will be distributed among the holders of the Ordinary Shares and the G Shares pro rata to the number of Ordinary Shares and G Shares held by them.
- 5.2 For the purposes of this Article 5:

- 5.2.1 a G Share is a **Participating G Share** (and **Participating G Shareholder** will be construed accordingly) for the purposes of this Article in relation to a distribution of Surplus Assets made after each Ordinary Shareholder has received an amount per Ordinary Share equal to the Hurdle Amount of that class of G Share.
- 5.2.2 a class of G Share with a lower Hurdle Amount is **senior** to a class of G Share with a higher Hurdle Amount and the class of G Share with a higher Hurdle Amount is **junior**.
- 5.3 If the amount of the Surplus Assets exceeds £100,000,000,000, the Deferred Shareholders shall be entitled, in priority to any distribution under Article 5.1.3, to be paid the sum of £1 in aggregate in respect of their Deferred Shares. This payment shall be deemed satisfied by payment to any one holder of Deferred Shares and the Deferred Shares shall not otherwise carry any right to share in any Surplus Assets.

# 6. EXIT PROVISIONS

- 6.1 Subject to Articles 10.1 and 40.1, on a Share Sale the Proceeds of Sale shall be distributed in the order of priority set out in Article 5 and the Directors shall not register any transfer of Shares if the Proceeds of Sale are not so distributed save in respect of any Shares not sold in connection with that Share Sale provided that if the Proceeds of Sale are not settled in their entirety upon completion of the Share Sale:
  - (a) the Directors shall not be prohibited from registering the transfer of the relevant Shares so long as the Proceeds of Sale that are settled have been distributed in the order of priority set out in Article 5; and
  - (b) the Shareholders shall take any action required by the Board to ensure that the Proceeds of Sale in their entirety are distributed in the order of priority set out in Article 5.

In the event that the Proceeds of Sale are distributed on more than one occasion (for any deferred or contingent consideration or otherwise), the consideration so distributed on any further occasion shall be paid by continuing the distribution from the previous distribution of consideration in the order of priority set out in Article 5.

- On an Asset Sale the surplus assets of the Company remaining after payment of its liabilities shall be distributed (to the extent that the Company is lawfully permitted to do so) in the order of priority set out in Article 5 provided always that if it is not lawful for the Company to distribute its surplus assets in accordance with the provisions of these Articles, the Shareholders shall take any action required by the Board (including, but without prejudice to the generality of this Article 6.2, actions that may be necessary to put the Company into voluntary liquidation) so that Article 5 applies.
- In the event of an Exit approved in accordance with the terms of these Articles (the **Proposed Exit**), all Shareholders shall consent to, vote for, raise no objections to and waive any applicable rights in connection with the Proposed Exit (**Actions**). The Shareholders shall be required to take all Actions with respect to the Proposed Exit as are required by the Board to facilitate the Proposed Exit. If any Shareholder fails to comply with the provisions of this Article, the Company shall be constituted the

agent of each defaulting Shareholder for taking the Actions as are necessary to effect the Proposed Exit and the Directors may authorise an officer or member to execute and deliver on behalf of such defaulting Shareholder the necessary documents and the Company may receive any purchase money due to the defaulting Shareholder in trust for each of the defaulting Shareholders.

- In the event of an Exit, the Series B Shareholders shall be entitled to receive the greater of: (i) the Series B Preference Amount; and (ii) the amount they would have been entitled to receive had the Series B Shares held by them converted into Ordinary Shares, in each case, subject to and in accordance with Articles 5, 6.1 and 6.2.
- In the event of an Exit, the Series A Shareholders shall be entitled to receive the greater of: (i) the Preference Amount; and (ii) the amount they would have been entitled to receive had the Series A Shares held by them converted into Ordinary Shares, in each case, subject to and in accordance with Articles 5, 6.1 and 6.2.

## 7. FOUNDATION SHARE BUYBACK OR FOUNDATION SHARE SALE

Prior to the completion of any Foundation Share Buyback or Foundation Share Sale, each Shareholder (other than the Foundation) shall provide all such consents as are required by the Board to facilitate the Foundation Share Buyback or Foundation Share Sale, including:

- (a) to waive any and all pre-emption and other rights (whether under any agreement that may be agreed from time to time between, inter alios, the Company and the Shareholders for the purposes of regulating the affairs of the Company and their relationship as Shareholders, the Articles, or otherwise) in connection with or that would prevent or impede any Foundation Share Buyback or Foundation Share Sale; and
- (b) to vote all Shares held by them in favour of any resolution (whether at a general meeting of the Company or pursuant to a written resolution of the Shareholders) or shareholder consent (whether under any agreement that may be agreed from time to time between, inter alios, the Company and the Shareholders for the purposes of regulating the affairs of the Company and their relationship as Shareholders, the Articles or otherwise) which is required in connection with the Foundation Share Buyback or Foundation Share Sale, including to approve any off-market share buyback contract in accordance with section 694 of the Act and/or approve a payment out of capital in respect of the Foundation Share Buyback in accordance with section 709 and Chapter 5 of Part 18 of the Act.

# 8. VOTES IN GENERAL MEETING AND WRITTEN RESOLUTIONS

8.1 The Series A Shares shall confer on each holder of Series A Shares the right to receive notice of and to attend, speak and vote at all general meetings of the Company and to receive and vote on proposed written resolutions of the Company.

- 8.2 Series B Shares shall confer on each holder of Series B Shares the right to receive notice of and to attend, speak and vote at all general meetings of the Company and to receive and vote on proposed written resolutions of the Company.
- 8.3 The Ordinary Shares shall confer on each holder of Ordinary Shares the right to receive notice of and to attend, speak and vote at all general meetings of the Company and to receive and vote on proposed written resolutions of the Company.
- 8.4 The G Shares shall not confer on their holder the right to receive notice of or to attend, speak or vote at general meetings of the Company nor shall they confer the right to receive or vote on proposed written resolutions of the Company.
- 8.5 The Deferred Shares shall not confer on their holder the right to receive notice of or to attend, speak or vote at general meetings of the Company nor shall they confer the right to receive or vote on proposed written resolutions of the Company.
- 8.6 Subject to Articles 8.7 to 8.9, where Shares confer a right to vote, on a show of hands each holder of such shares who (being an individual) is present in person or by proxy or (being a corporation) is present by a duly authorised representative or by proxy shall have one vote and on a poll each such holder so present shall have one vote for each Share held by him.
- 8.7 If at any time prior to Exit the Shares held by WEIF constitute more than 19.5% of the total voting share capital of the Company, WEIF's Shares shall be limited in aggregate to 19.5% of the total number of votes, such votes to be split equally on a fractional basis amongst the Shares held by WEIF. WIM may at any time prior to or upon transfer of the Shares held by WEIF elect to have normal voting rights reapply to such Shares.
- 8.8 Notwithstanding any other provisions of the Articles, for so long as WPCT is the holder of any Shares and any provision would result in WCPT being able to exercise more than 49% of the votes capable of being exercised at any particular meeting, the number of votes attaching to all Shares held by WPCT shall so long as this situation pertains, be restricted so that the votes conferred on WPCT in respect of all Shares held by it shall represent 49% of the votes capable of being exercised.
- 8.9 To the extent permissible for regulatory purposes and subject to appropriate structuring, any voting rights that WEIF and/or WPCT are unable to exercise due to the restrictions in Articles 8.7 and 8.8 above shall be exercisable by Malin, provided this does not in any way increase the voting rights of the Shares held by Malin, or affect the voting rights of other Shareholders.
- 8.10 No voting rights attached to a share which is nil paid or partly paid may be exercised:
  - (a) at any general meeting, at any adjournment of it or at any poll called at or in relation to it; or
  - (b) on any proposed written resolution,

unless all of the amounts payable to the Company in respect of that share have been paid.

# 9. CONSOLIDATION OF SHARES

- 9.1 Whenever as a result of a consolidation of Shares any Shareholders would become entitled to fractions of a Share, the Directors may, on behalf of those Shareholders, sell the Shares representing the fractions for the best price reasonably obtainable to any person (including, subject to the provisions of the Act, the Company) and distribute the net proceeds of sale in due proportion among those Shareholders, and the Directors may authorise any person to execute an instrument of transfer of the Shares to, or in accordance with the directions of, the purchaser. The transferee shall not be bound to see to the application of the purchase money nor shall his title to the Shares be affected by any irregularity in or invalidity of the proceedings in reference to the sale.
- 9.2 When the Company sub-divides or consolidates all or any of its Shares, the Company may, subject to the Act and to these Articles, by ordinary resolution determine that, as between the Shares resulting from the sub-division or consolidation, any of them may have any preference or advantage or be subject to any restriction as compared with the others.

## 10. CONVERSION OF SERIES A SHARES

- 10.1 The Company shall use reasonable endeavours to give at least 10 Business Days' notice in writing to the holders of the Series A Shares of any proposed distribution of assets in accordance with Article 5, and any distribution of Proceeds of Sale in accordance with Article 6 setting out the approximate amount which would be paid per Series A Share and per Ordinary Share on such proposed distribution.
- Any holder of Series A Shares shall be entitled, by notice in writing to the Company, to require conversion into Ordinary Shares of all of the fully paid Series A Shares held by them at any time and those Series A Shares shall convert automatically on the date of such notice (the **Conversion Date**), provided that the holder may in such notice, state that conversion of its Series A Shares into Ordinary Shares is conditional upon the occurrence of one or more events (the **Conditions**).
- 10.3 All of the fully paid Series A Shares shall automatically convert into Ordinary Shares:
  - (a) on the date of receipt by the Company of a written notice given by the Series A Majority requiring conversion of the Series A Shares (which date shall be treated as the Conversion Date); or
  - (b) immediately upon the occurrence of a Qualifying IPO.
- In the case of (i) Articles 10.2 and 10.3(a), not more than five Business Days after the Conversion Date or (ii) in the case of Article 10.3(b), at least five Business Days prior to the occurrence of the Qualifying IPO, each holder of the relevant Series A Shares shall deliver the certificate (or an indemnity for lost certificate in a form acceptable to the Board) in respect of the Series A Shares being converted to the Company at its registered office for the time being.
- 10.5 Where conversion is mandatory on the occurrence of a Qualifying IPO, that conversion will be effective only immediately prior to and conditional upon such Qualifying IPO (and **Conversion Date** shall be construed accordingly) and, if such

Qualifying IPO does not become effective or does not take place, such conversion shall be deemed not to have occurred. In the event of a conversion under Article 10.2, if the Conditions have not been satisfied or waived by the relevant holder by the Conversion Date such conversion shall be deemed not to have occurred.

- On the Conversion Date, the relevant Series A Shares shall without further authority than is contained in these Articles stand converted into Ordinary Shares on the basis of one Ordinary Share for each Series A Share held (the **Conversion Ratio**), and the Ordinary Shares resulting from that conversion shall in all other respects rank pari passu with the existing issued Ordinary Shares.
- The Company shall on the Conversion Date enter the holder of the converted Series A Shares on the register of members of the Company as the holder of the appropriate number of Ordinary Shares and, subject to the relevant holder delivering its certificate(s) (or an indemnity for lost certificate in a form acceptable to the Board) in respect of the Series A Shares in accordance with this Article, the Company shall within 10 Business Days of the Conversion Date forward to such holder of Series A Shares by post to his address shown in the register of members, free of charge, a definitive certificate for the appropriate number of fully paid Ordinary Shares.
- On the Conversion Date (or as soon afterwards as it is possible to calculate the amount payable), the Company will, if it has sufficient Available Profits, pay to holders of the Series A Shares falling to be converted a dividend equal to all accruals of dividends in relation to those Series A Shares to be calculated on a daily basis down to and including the day immediately preceding the Conversion Date. If the Company has insufficient Available Profits to pay all such accruals of dividends in full then it will pay the same to the extent that it is lawfully able to do so.
- 10.9 The Conversion Ratio shall from time to time be adjusted in accordance with the provisions of this Article:
  - (a) if Series A Shares remain capable of being converted into new Ordinary Shares and there is a consolidation and/or sub-division of Ordinary Shares, the Conversion Ratio shall be adjusted by an amount, which in the opinion of the Board is fair and reasonable, to maintain the right to convert so as to ensure that each Series A Shareholder is in no better or worse position as a result of such consolidation or sub-division, such adjustment to become effective immediately after such consolidation or sub-division;
  - (b) if Series A Shares remain capable of being converted into Ordinary Shares, on an allotment of fully-paid Ordinary Shares pursuant to a capitalisation of profits or reserves to holders of Ordinary Shares the Conversion Ratio shall be adjusted by an amount, which in the opinion of the Board is fair and reasonable, to maintain the right to convert so as to ensure that each Series A Shareholder is in no better or worse position as a result of such capitalisation of profits or reserves, such adjustment to become effective as at the record date for such issue.
- 10.10 If any Series A Shareholder becomes entitled to fractions of an Ordinary Share as a result of conversion (**Fractional Holders**), the Directors may (in their absolute

discretion) deal with these fractions as they think fit on behalf of the Fractional Holders. In particular, the Directors may aggregate and sell the fractions to a person for the best price reasonably obtainable and distribute the net proceeds of sale in due proportions among the Fractional Holders or may ignore fractions or accrue the benefit of such fractions to the Company rather than the Fractional Holder. For the purposes of completing any such sale of fractions, the chairman of the Company or, failing him, the secretary will be deemed to have been appointed the Fractional Holder's agent for the purpose of the sale.

10.11 If a doubt or dispute arises concerning an adjustment of the Conversion Ratio in accordance with Article 10.9, or if so requested by a Series A Majority, the Board shall refer the matter to the Auditors for determination who shall make available to all Shareholders their report and whose certificate as to the amount of the adjustment is, in the absence of manifest error, conclusive and binding on all concerned and their costs shall be met by the Company.

## 11. ANTI-DILUTION PROTECTION

If New Securities are issued by the Company at a price per New Security which equates to less than the Series A Price (a Qualifying Issue) (which in the event that the New Security is not issued for cash shall be a price certified by the Auditors acting as experts and not as arbitrators as being in their opinion the current cash value of the new consideration for the allotment of the New Securities) then the Company shall, unless the Series A Majority shall have specifically waived the rights of all of the holders of Series A Shares, as soon as practicable following the Qualifying Issue (or, where such Qualifying Issue forms part of an Investment Round, as soon as practicable following the final closing of such Investment Round) issue to each holder of Series A Shares (the Exercising Investor) a number of new Ordinary Shares determined by applying the following formula (and rounding the product, N, down to the nearest whole share), subject to adjustment as certified in accordance with Article 11.3 (the Anti-Dilution Shares):

$$N = \left( \left( \frac{SIP}{WA} \right) \times Z \right) - Z$$

Where

N = Number of Anti-Dilution Shares to be issued to the Exercising Investor

$$WA = \frac{(SIPxESC) + (QISPxNS)}{(ESC + NS)}$$

SIP = Series A Price

ESC = the number of Equity Shares and G Shares in issue plus the aggregate number of Equity Shares and G Shares in respect of which options to subscribe have been granted, or which are subject to convertible securities (including but not limited to warrants) in each case immediately prior to the Qualifying Issue

QISP = the lowest per share price of the New Securities issued pursuant to the Qualifying Issue (which in the event that that New Security is not issued for cash shall be the sum certified by the Auditors acting as experts and not arbitrators as being in their opinion the current cash value of the non-cash consideration for the allotment of the New Security)

NS = the number of New Securities issued pursuant to the Qualifying Issue

Z = the number of Series A Shares held by the Exercising Investor prior to the Qualifying Issue.

# 11.2 The Anti-Dilution Shares shall:

- (a) be paid up by the automatic capitalisation of available reserves of the Company, unless and to the extent that the same shall be impossible or unlawful or a majority of the Exercising Investors shall agree otherwise, in which event the Exercising Investors shall be entitled to subscribe for the Anti-Dilution Shares in cash at par and the entitlement of such Exercising Investors to Anti-Dilution Shares shall be increased by adjustment to the formula set out in Article 11.1 so that the Exercising Investors shall be in no worse position than if they had not so subscribed at par. In the event of any dispute between the Company and any Exercising Investor as to the effect of Article 11.1 or this Article 11.2, the matter shall be referred (at the cost of the Company) to the Auditors for certification of the number of Anti-Dilution Shares to be issued. The Auditors' certification of the matter shall in the absence of manifest error be final and binding on the Company and the Exercising Investor; and
- (b) subject to the payment of any cash payable pursuant to Article 11.2(a) (if applicable), be issued, credited fully paid up in cash and shall rank pari passu in all respects with the existing Ordinary Shares, within five Business Days of the expiry of the offer being made by the Company to the Exercising Investor and pursuant to Article 11.2(a).
- In the event of any Bonus Issue or Reorganisation, the Series A Price shall also be subject to adjustment on such basis as may be agreed by the Company with the Series A Majority within 10 Business Days after any Bonus Issue or Reorganisation. If the Company and the Series A Majority cannot agree such adjustment it shall be referred to the Auditors whose determination shall, in the absence of manifest error, be final and binding on the Company and each of the Shareholders. The costs of the Auditors shall be borne by the Company.
- 11.4 For the purposes of this Article 11 any Shares held as Treasury Shares by the Company shall be disregarded when calculating the number of Anti-Dilution Shares to be issued.

# 12. CONVERSION OF G ORDINARY SHARES

12.1 If any G Shares are transferred in accordance with these Articles to a Shareholder who is not an Employee or former Employee (or a person holding G Shares on their behalf), such Shareholder shall be entitled, by notice in writing to the Company (Shareholder G Share Conversion Notice), to require all of the G Shares of a

particular class held by them to be converted into Ordinary Shares and Deferred Shares. The G Shares shall be converted into:

(a) such number of Ordinary Shares as is the result of the following formula:

$$O = \frac{GC \times GP}{(GP + H)}$$

where

GC = the number of G Shares of a particular class to be converted under the G Share Conversion Notice

GP = the purchase price per share paid by the Shareholder serving the G Share Conversion Notice for the G Shares to be converted

H = the Hurdle Amount for the class of G Share to be converted

O = the number of Ordinary Shares arising on the conversion of the relevant G Shares

and

- (b) such number of Deferred Shares as shall be calculated by dividing the remaining aggregate balance of the nominal amount of the G Shares not converted into Ordinary Shares pursuant to Article 12.1(a) by the nominal amount per share of the Deferred Shares.
- Where any G Shares are held by an Employee or former Employee (or a person holding G Shares on their behalf), the Company may where it is entitled to do so under the terms of a G Share Subscription Agreement, by notice in writing (Company G Share Conversion Notice, which, together with a Shareholder G Share Conversion Notice is a G Share Conversion Notice) served on the holders of such G Shares, require the conversion of such number of G Shares into Deferred Shares as is prescribed by or in accordance with such G Share Subscription Agreement.
- The G Shares shall convert automatically upon the service of a G Share Conversion Notice (the date of conversion being a **G Share Conversion Date**). On the G Share Conversion Date, the relevant G Shares shall without further authority than is contained in these Articles stand converted into Ordinary Shares and/or Deferred Shares on the basis set out in Article 12.1 or 12.2 as applicable and the Ordinary Shares and Deferred Shares resulting from that conversion shall in all respects rank pari passu with the existing issued Ordinary Shares and Deferred Shares.
- The Company shall on the G Share Conversion Date enter the holder of the converted G Shares on the register of members of the Company as the holder of the appropriate number of Ordinary Shares and/or Deferred Shares and, subject to the relevant holder delivering its certificate(s) (or an indemnity for lost certificate in a form acceptable to the Board) in respect of the G Shares in accordance with this Article, the Company shall, if applicable, within 10 Business Days of the G Conversion Date forward to such holder of G Shares by post to his address shown

in the register of members, free of charge, a definitive certificate for the appropriate number of fully paid Ordinary Shares. The Company shall not be required to issue any certificate for any Deferred Shares.

If any Shareholder becomes entitled to fractions of an Ordinary Share as a result of conversion under this Article 12 (Conversion of G Ordinary Shares), the Directors may (in their absolute discretion) deal with these fractions as they think fit on behalf of the Fractional Holders. In particular, the Directors may aggregate and sell the fractions to a person for the best price reasonably obtainable and distribute the net proceeds of sale in due proportions among the Fractional Holders or may ignore fractions or accrue the benefit of such fractions to the Company rather than the Fractional Holder. For the purposes of completing any such sale of fractions, the chairman of the Company or, failing him, the secretary will be deemed to have been appointed the Fractional Holder's agent for the purpose of the sale.

## 13. VARIATION OF RIGHTS

- 13.1 Subject to Articles 13.3 and 13.4, whenever the share capital of the Company is divided into different classes of shares, the special rights attached to any such class may only be varied or abrogated (either whilst the Company is a going concern or during or in contemplation of a winding-up) with the consent in writing of the holders of more than 75 per cent. in nominal value of the issued shares of that class.
- 13.2 The creation of a new class of shares with Series A Majority Consent and Series B Majority Consent which has preferential rights to one or more existing classes of shares shall not constitute a variation of the rights of those existing classes of shares.
- The special rights attaching to the G Shares may be varied by a special resolution of the Company, without the need for any consent or resolution of the G Shareholders provided that any variation to the Hurdle Amount for any class of G Share made after the date of issue of that class of G Share shall, except as provided in Article 13.4, require a special resolution of the Company and the consent in writing of the holders of more than 75 per cent. in nominal value of the issued shares of that class.
- In the event of a Bonus Issue or Reorganisation or a disposal by the Company (whether by demerger or otherwise) of a substantial proportion of its assets, the Directors may, with Series B Majority Consent, make such adjustments to the Hurdle Amounts as they consider fair and reasonable so as to procure that the holders of each class of G Share are in no better or worse position as a result of such event.
- 13.5 The special rights attaching to the Deferred Shares may be varied by a special resolution of the Company, without the need for any consent or resolution of the Deferred Shareholders.

#### 14. ALLOTMENT OF NEW SHARES OR OTHER SECURITIES: PRE-EMPTION

14.1 Sections 561(1) and 562(1) to (5) (inclusive) of the Act do not apply to an allotment of Equity Securities made by the Company.

- 14.2 Subject to Article 14.9, no new Series A Shares may be allotted without a special resolution of the Company and Series A Majority Consent and Series B Majority Consent.
- 14.3 Subject to Article 14.9, no new Series B Shares may be allotted without a special resolution of the Company and Series A Majority Consent and Series B Majority Consent.
- 14.4 Unless otherwise agreed by special resolution, if the Company proposes to allot any New Securities those New Securities shall not be allotted to any person unless the Company has in the first instance offered them, in accordance with and subject to the provisions of Articles 14.5-14.7, to:
  - (a) first (and in priority to any other classes of Shares), the Series B Shareholders and the Series A Shareholders, such that the Series B Shareholders and the Series A Shareholders shall be entitled to subscribe for New Securities on the same terms and at the same price as those New Securities are being offered to other persons and, as between each Shareholder, pro rata to its respective holding of Series B Shares and Series A Shares (calculated, as nearly as may be without involving fractions, as a proportion of the total number of the respective Series B Shares and Series A Shares in issue immediately prior to the issuance of the New Securities, as if the Series B Shares and Series A Shares constituted one and the same class);
  - (b) second (to the extent that there remain any New Securities for which the Series B Shareholders and the Series A Shareholders have not applied) to the Ordinary Shareholders on the same terms and at the same price as the New Securities offered to the Series B Shareholders and the Series A Shareholders pursuant to Article 14.4(a) and, as between each Shareholder, pro rata to its holding of Ordinary Shares (calculated, as nearly as may be without involving fractions, as a proportion of the total number of Ordinary Shares in issue immediately prior to the issuance of the New Securities); and
  - (c) third (to the extent that there remain any New Securities for which the Ordinary Shareholders have not applied) to the Series B Shareholders on the same terms and at the same price as the New Securities offered to the Series B Shareholders and the Series A Shareholders pursuant to Article 14.4(a) and, as between each Shareholder, pro rata to its holding of Series B Shares (calculated, as nearly as may be without involving fractions, as a proportion of the total number of Series B Shares in issue immediately prior to the issuance of the New Securities).

## 14.5 An offer of New Securities:

(a) to Series B Shareholders and Series A Shareholders pursuant to Article 14.4(a) shall be open for acceptance by the Series B Shareholders and the Series A Shareholders from the date of the offer to the date falling five Business Days after the date of the offer (inclusive) (the First Subscription Period) and give details of the number and subscription price of the New Securities;

- (b) to Ordinary Shareholders pursuant to Article 14.4(b) shall be made by the Company within three Business Days of the expiry of the First Subscription Period (provided that, at such time, there remain any New Securities for which the Series B Shareholders and the Series A Shareholders have not applied), shall be open for acceptance by the Ordinary Shareholders for a period of 10 Business Days (the **Second Subscription Period**) and shall give details of the number and subscription price of the balance of the New Securities (being those New Securities for which the Series B Shareholders and the Series A Shareholders have not applied);
- (c) to Series B Shareholders pursuant to Article 14.4(c) shall be made by the Company within three Business Days of the expiry of the Second Subscription Period (provided that, at such time, there remain any New Securities for which the Ordinary Shareholders have not applied), shall be open for acceptance by the Series B Shareholders for a period of five Business Days (the **Third Subscription Period**) and shall give details of the number and subscription price of the balance of the New Securities (being those New Securities for which the Ordinary Shareholders have not applied);
- (d) shall be in writing and shall specify the number, price and terms of payment of the New Securities on offer;
- (e) shall invite each recipient to state in writing the number of New Securities for which it wishes to subscribe; and
- (f) may stipulate that any Shareholder who wishes to subscribe for a number of New Securities in excess of the proportion to which each is entitled shall in their acceptance state the number of excess New Securities for which they wish to subscribe.

# 14.6 If:

- (a) at the end of the First Subscription Period, the number of New Securities applied for is equal to or exceeds the number of New Securities on offer, the New Securities shall be allotted to each Series B Shareholder and Series A Shareholder who has applied for New Securities (the Subscribing Series B Shareholders and the Subscribing Series A Shareholders, respectively) pro rata to its respective holding of Series B Shares (calculated as a proportion of the total number of Series B Shares held by Subscribing Series B Shareholders) and Series A Shares (calculated as a proportion of the total number of Series A Shares (calculated as a proportion of the total number of Series A Shares held by Subscribing Series A Shareholders) until all New Securities have been allotted (as nearly as may be without involving fractions);
- (b) at the end of the Second Subscription Period, the number of New Securities applied for is equal to or exceeds the number of New Securities on offer, the New Securities shall be allotted to each Shareholder who has applied for New Securities (the Subscribing Shareholders) in the order of priority set out in Article 14.4 and pro rata to each Shareholder's respective holding of Series B Shares and Series A Shares (for the purposes of Article 14.4(a)) or Ordinary

Shares (for the purposes of Article 14.4(b)), in each case, calculated as a proportion of the relevant class of Shares held by Subscribing Shareholders, until all New Securities have been allotted (as nearly as may be without involving fractions); or

(c) at the end of the Third Subscription Period, the number of New Securities applied for is equal to or exceeds the number of New Securities on offer, the New Securities shall be allotted to each Shareholder who has applied for New Securities in the order of priority set out in Article 14.4 and *pro rata* to each Shareholder's respective holding of Series B Shares and Series A Shares (for the purposes of Article 14.4(a)), Ordinary Shares (for the purposes of Article 14.4(b)) or Series B Shares (for the purposes of Article 14.4(c)), in each case, calculated as a proportion of the relevant class of Shares held by Subscribing Shareholders, until all New Securities have been allotted (as nearly as may be without involving fractions),

save that, in each case, no allocation shall be made to a Shareholder of more than the maximum number of New Securities which it has stated it is willing to buy.

- 14.7 If, at the end of the Third Subscription Period, the number of New Securities applied for is less than the number of New Securities or there remain any New Securities that are not capable of being allocated between the accepting Shareholders except by way of fractions, then any remaining New Securities shall be offered, subject to Article 14.8, to any other person as the Directors may determine at the same price and on the same terms as the offer to the Subscribing Shareholders.
- 14.8 Subject to the requirements of Articles 14.2 to 14.7 (inclusive) and to the provisions of section 551 of the Act, any New Securities shall be at the disposal of the Board who may allot, grant options over or otherwise dispose of them to any persons at those times and generally on the terms and conditions they think proper.
- 14.9 The provisions of Articles 14.2 to 14.7 (inclusive) shall not apply to:
  - (a) options to subscribe for Ordinary Shares under the Share Option Plans;
  - the issue of, or grant of options to subscribe for, G Shares to Employees or prospective Employees;
  - (c) the issue of any new Series B Shares in connection with any Subsequent Closing;
  - (d) New Securities issued or granted in order for the Company to comply with its obligations under these Articles including, but not limited to the Anti-Dilution Shares and the Series B Anti-Dilution Shares;
  - (e) New Securities issued as a result of a bonus issue of shares which has been approved in writing by a Series A Majority and Series B Majority; and
  - (f) Shares or options for Shares issued or granted to the Investors and Existing Shareholders in accordance with the terms of any shareholders' agreement or similar document in force between some or all of the Shareholders and the Company from time to time.

- 14.10 Any New Securities offered under this Article 14 to a holder of Equity Shares may be accepted in full or part only by a Member Of The Same Fund Group as that Investor or a Member of the same Group as that Investor in accordance with the terms of this Article 14.
- 14.11 No Shares shall be allotted (nor any Treasury Shares be transferred) to any Employee, Director, prospective Employee or prospective director of the Company (or any nominee for such person), who in the opinion of the Board is subject to taxation in the United Kingdom, unless such person has entered into a joint section 431 ITEPA election with the Company if so required by the Company.
- 14.12 The holders of Ordinary Shares, Series A Shares and Series B Shares may waive their respective rights under this Article 14 with the consent in writing of the holders of more than 75 per cent. in nominal value of the issued shares of that class (in which case such waiver shall be binding on the entire class).

# 15. TRANSFERS OF SHARES — GENERAL

- 15.1 In Articles 15 to 21 inclusive, reference to the transfer of a Share includes the transfer or assignment of a beneficial or other interest in that Share or the creation of a trust or Encumbrance over that Share and reference to a Share includes a beneficial or other interest in a Share.
- 15.2 No Share may be transferred unless the transfer is made in accordance with these Articles.
- 15.3 If a Shareholder transfers or purports to transfer a Share otherwise than in accordance with these Articles he will be deemed immediately to have served a Transfer Notice in respect of all Shares held by him.
- Any transfer of a Share by way of sale which is required to be made under Articles 17 to 21 (inclusive) will be deemed to include a warranty that the transferor sells with full title guarantee.
- 15.5 The Directors may refuse to register a transfer if:
  - (a) it is a transfer of a Share to a bankrupt, a minor or a person of unsound mind;
  - (b) the transfer is to an Employee, Director or prospective Employee or prospective director of the Company (or any nominee for such person), who in the opinion of the Board is subject to taxation in the United Kingdom, and such person has not entered into a joint section 431 ITEPA election with the Company;
  - (c) it is a transfer of a Share which is not fully paid:
    - (i) to a person of whom the Directors do not approve; or
    - (ii) on which Share the Company has a lien;
  - (d) the transfer is not lodged at the registered office or at such other place as the Directors may appoint;

- (e) the transfer is not accompanied by the certificate for the Shares to which it relates (or an indemnity for lost certificate in a form acceptable to the Board) and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer;
- (f) the transfer is in respect of more than one class of Shares;
- (g) the transfer is in favour of more than four transferees; or
- (h) these Articles otherwise provide that such transfer shall not be registered.

If the Directors refuse to register a transfer, the instrument of transfer must be returned to the transferee with the notice of refusal unless they suspect that the proposed transfer may be fraudulent.

- The Directors may, as a condition to the registration of any transfer of shares in the Company (whether pursuant to a Permitted Transfer or otherwise), require the transferee to execute and deliver to the Company a deed agreeing to be bound by the terms of any shareholders' agreement or similar document in force between some or all of the Shareholders and the Company in any form as the Directors may reasonably require (but not so as to oblige the transferee to have any obligations or liabilities greater than those of the proposed transferor under any such agreement or other document) and if any condition is imposed in accordance with this Article 15.6 the transfer may not be registered unless that deed has been executed and delivered to the Company's registered office by the transferee.
- 15.7 To enable the Directors to determine whether or not there has been any disposal of shares in the capital of the Company (or any interest in shares in the capital of the Company) in breach of these Articles the Directors may require any holder or the legal personal representatives of any deceased holder or any person named as transferee in any transfer lodged for registration or any other person who the Directors may reasonably believe to have information relevant to that purpose, to furnish to the Company that information and evidence the Directors may request regarding any matter which they deem relevant to that purpose, including (but not limited to) the names, addresses and interests of all persons respectively having interests in the shares in the capital of the Company from time to time registered in the holder's name. If the information or evidence is not provided to enable the Directors to determine to their reasonable satisfaction that no breach has occurred, or where as a result of the information and evidence the Directors are reasonably satisfied that a breach has occurred, the Directors shall immediately notify the holder of such shares in the capital of the Company in writing of that fact and the following shall occur:
  - (a) the relevant shares shall cease to confer upon the holder of them (including any proxy appointed by the holder) any rights to vote (whether on a show of hands or on a poll and whether exercisable at a general meeting or on a written resolution of the Company or at any separate meeting or written resolution of the class in question) provided that, at the election of the relevant Investor, such rights shall not cease if as a result of such cessation the Company shall become a Subsidiary of an Investor; or

- (b) the withholding of payment of all dividends or other distributions otherwise attaching to the relevant shares or to any further shares issued in respect of those shares; and
- (c) the holder may be required at any time following receipt of the notice to transfer some or all of its Shares to any person(s) at the price that the Directors may require by notice in writing to that holder.

The rights referred to in (a) and (b) above may be reinstated by the Board and shall in any event be reinstated upon the completion of any transfer referred to in (c) above.

- 15.8 In any case where the Board requires a Transfer Notice to be given in respect of any Shares, if a Transfer Notice is not duly given within a period of 10 Business Days of demand being made, a Transfer Notice shall be deemed to have been given at the expiration of that period.
- 15.9 If a Transfer Notice is required to be given by the Board or is deemed to have been given under these Articles, the Transfer Notice, unless otherwise specified in the Articles, will be treated as having specified that:
  - (a) the Transfer Price for the Sale Shares will be as agreed between the Board (any Director who is a Seller or with whom the Seller is connected (within the meaning of section 252 of the Act) not voting) and the Seller, or, failing agreement within five Business Days after the date on which the Board becomes aware that a Transfer Notice has been deemed to have been given, will be the Fair Value of the Sale Shares;
  - (b) it does not include a Minimum Transfer Condition (as defined in Article 17.2(d)); and
  - (c) the Seller wishes to transfer all of the Shares held by it.
- 15.10 Shares may be transferred by means of an instrument of transfer in any usual form or any other form approved by the Directors, which is executed by or on behalf of:
  - (a) the transferor; and
  - (b) (if any of the shares is partly or nil paid) the transferee.
- 15.11 No Deferred Share may be transferred without the prior consent of the Board

## 16. PERMITTED TRANSFERS

A Shareholder (who is not a Permitted Transferee) (the **Original Shareholder**) may transfer all or any of his or its Shares to a Permitted Transferee without restriction as to price or otherwise, provided that an Investor shall not be permitted to transfer Shares to another Investor (a **Transferee Investor**) to the extent that such transfer would result in the Transferee Investor acquiring an aggregate holding of 25 per cent or more of the total issued share capital in the Company unless such Transferee Investor acquires such Shares in accordance with Article 17.

- Shares previously transferred as permitted by Article 16.1 may be transferred by the transferee to any other Permitted Transferee of the Original Shareholder without restriction as to price or otherwise.
- Where under the provision of a deceased Shareholder's will or laws as to intestacy, the persons legally or beneficially entitled to any Shares, whether immediately or contingently, are Permitted Transferees of the deceased Shareholder, the legal representative of the deceased Shareholder may transfer any Share to those Permitted Transferees, in each case without restriction as to price or otherwise.
- 16.4 If a Permitted Transferee who was a Member of the same Group as the Original Shareholder ceases to be a Member of the same Group as the Original Shareholder, the Permitted Transferee must not later than five Business Days after the date on which the Permitted Transferee so ceases, transfer the Shares held by it to the Original Shareholder or a Member of the same Group as the Original Shareholder (which in either case is not in liquidation) without restriction as to price or otherwise failing which it will be deemed to have given a Transfer Notice in respect of those Shares.
- If a Permitted Transferee who was a Member Of The Same Fund Group as the Original Shareholder ceases to be a Member Of The Same Fund Group, the Permitted Transferee must not later than five Business Days after the date on which the Permitted Transferee so ceases, transfer the Shares held by it to the Original Shareholder or a Member Of The Same Fund Group as the Original Shareholder (which in either case is not in liquidation) without restriction as to price or otherwise failing which it will be deemed to give a Transfer Notice in respect of such Shares.
- 16.6 Trustees may (i) transfer Shares to a Qualifying Company or (ii) transfer Shares to the Original Shareholder or to another Permitted Transferee of the Original Shareholder or (iii) transfer Shares to the new or remaining trustees upon a change of Trustees without restrictions as to price or otherwise.
- 16.7 No transfer of Shares may be made to Trustees unless the Board is satisfied:
  - (a) with the terms of the trust instrument and in particular with the powers of the Trustees;
  - (b) with the identity of the proposed Trustees;
  - (c) the proposed transfer will not result in 50 per cent. or more of the aggregate of the Company's equity share capital being held by Trustees of that and any other trusts; and
  - (d) that no costs incurred in connection with the setting up or administration of the Family Trust in question are to be paid by the Company.
- 16.8 If a Permitted Transferee who is a Qualifying Company of the Original Shareholder ceases to be a Qualifying Company of the Original Shareholder, it must within five Business Days of so ceasing, transfer the Shares held by it to the Original Shareholder (or, to any Permitted Transferee of the Original Shareholder) (and may do so without restriction as to price or otherwise) failing which it will be deemed

(unless it obtains the approval of the Board), to have given a Transfer Notice in respect of such Shares.

- 16.9 If a Permitted Transferee who is a spouse or Civil Partner of the Original Shareholder ceases to be a spouse or Civil Partner of the Original Shareholder whether by reason of divorce or otherwise he must, within 15 Business Days of so ceasing either:
  - (a) execute and deliver to the Company a transfer of the Shares held by him to the Original Shareholder (or, to any Permitted Transferee of the Original Shareholder) for such consideration as may be agreed between them; or
  - (b) give a Transfer Notice to the Company in accordance with Article 17.2, failing which he shall be deemed to have given a Transfer Notice.
- On the death (subject to Article 16.3), bankruptcy, liquidation, administration or administrative receivership of a Permitted Transferee (other than a joint holder) his personal representatives or trustee in bankruptcy, or its liquidator, administrator or administrative receiver must within five Business Days after the date of the grant of probate, the making of the bankruptcy order or the appointment of the liquidator, administrator or the administrative receiver execute and deliver to the Company a transfer of the Shares held by the Permitted Transferee without restriction as to price or otherwise. The transfer shall be to the Original Shareholder if still living (and not bankrupt or in liquidation) or, if so directed by the Original Shareholder, to any Permitted Transferee of the Original Shareholder. If the transfer is not executed and delivered within five Business Days of such period or if the Original Shareholder has died or is bankrupt or is in liquidation, administration or administrative receivership, the personal representative or trustee in bankruptcy or liquidator, administrator or administrative receiver will be deemed to have given a Transfer Notice.
- 16.11 A transfer of any Shares approved by the Board may be made without restriction as to price or otherwise and with any such conditions as may be imposed and each such transfer shall be registered by the Directors.
- Any Shares may at any time be transferred where there is a sale of the entire issued share capital of the Company to a Holding Company, which has been approved by a majority of the Board.
- 16.13 The Company shall only be permitted to sell or transfer any Shares held as Treasury Shares to any person.
- 16.14 An Employee or former Employee (or the Employee Nominee for such person) may transfer Shares under Secondary Market Arrangements with the prior approval of the Board.

## 17. TRANSFERS OF SHARES SUBJECT TO PRE-EMPTION RIGHTS

17.1 Save in the case of a Permitted Transfer or where the provisions of Articles 20 or 21 apply, any transfer of Shares by a Shareholder shall be subject to the preemption rights contained in this Article 17.

- 17.2 A Shareholder who wishes to transfer Shares (a **Seller**) shall, except as otherwise provided in these Articles, before transferring or agreeing to transfer any Shares give notice in writing (a **Transfer Notice**) to the Company specifying:
  - (a) the number of Shares which he wishes to transfer (the Sale Shares);
  - (b) if he wishes to sell the Sale Shares to a third party, the name of the proposed transferee;
  - (c) the price at which he wishes to transfer the Sale Shares; and
  - (d) whether the Transfer Notice is conditional on all or a specific number of the Sale Shares being sold to Shareholders (a **Minimum Transfer Condition**).

If no cash price is specified by the Seller, the price at which the Sale Shares are to be transferred (the **Transfer Price**) must be agreed by the Board. In addition, if the price is not specified in cash, an equivalent cash value price must be agreed between the Seller and the Board. In both cases, the price will be deemed to be the Fair Value of the Sale Shares if no price is agreed within five Business Days of the Company receiving the Transfer Notice.

- 17.3 Except with the consent of the Board, no Transfer Notice once given or deemed to have been given under these Articles may be withdrawn.
- 17.4 A Transfer Notice constitutes the Company the agent of the Seller for the sale of the Sale Shares at the Transfer Price.
- 17.5 As soon as practicable following the later of:
  - (a) receipt of a Transfer Notice; or
  - (b) in the case where the Transfer Price has not been agreed, the determination of the Transfer Price under Article 18,

the Board shall offer the Sale Shares for sale to the Shareholders in the manner set out in Articles 17.6 and 17.7. Each offer must be in writing and give details of the number and Transfer Price of the Sale Shares offered.

- 17.6 Transfers: Offer
- 17.6.1 The Board shall offer the Sale Shares at the Transfer Price to:
  - (a) first (and in priority to any other classes of Shares), the Series B Shareholders and the Series A Shareholders (other than the Seller) and, as between each Shareholder, pro rata to its respective holding of Series B Shares and Series A Shares (calculated, as nearly as may be without involving fractions, as a proportion of the total number of the respective Series B Shares and Series A Shares in issue, as if the Series B Shares and Series A Shares constituted one and the same class);
  - (b) second (to the extent that there remain any Sale Shares for which the Series B Shareholders and Series A Shareholders have not applied) to the Ordinary Shareholders and, as between each Shareholder, pro rata to its holding of

- Ordinary Shares (calculated, as nearly as may be without involving fractions, as a proportion of the total number of Ordinary Shares in issue); and
- (c) third (to the extent that there remain any Sale Shares for which the Ordinary Shareholders have not applied) to the Series B Shareholders and, as between each Shareholder, pro rata to its holding of Series B Shares (calculated, as nearly as may be without involving fractions, as a proportion of the total number of Series B Shares in issue),

in each case, in accordance with Articles 17.6.2-17.6.5.

## 17.6.2 An offer of Sale Shares:

- (a) to Series B Shareholders and Series A Shareholders pursuant to Article 17.6.1(a) shall be open for acceptance by the Series B Shareholders and Series A Shareholders from the date of the offer to the date falling five Business Days after the date of the offer (inclusive) (the First Offer Period) and shall invite such Shareholders to apply in writing for the maximum number of Sale Shares they wish to buy;
- (b) to Ordinary Shareholders pursuant to Article 17.6.1(b) shall be made by the Company within three Business Days of the expiry of the First Offer Period (provided that, at such time, there remain any Sale Shares for which the Series B Shareholders and Series A Shareholders have not applied), shall be open for acceptance by the Ordinary Shareholders for a period of 10 Business Days (the **Second Offer Period**) and shall invite such Shareholders to apply in writing for the balance of the Sale Shares (being those Sale Shares for which the Series B Shareholders and the Series A Shareholders have not applied); and
- (c) to Series B Shareholders pursuant to Article 17.6.1(c) shall be made by the Company within three Business Days of the expiry of the Second Offer Period (provided that, at such time, there remain any New Securities for which the Ordinary Shareholders have not applied), shall be open for acceptance by the Series B Shareholders for a period of five Business Days (the **Third Offer Period**) and shall invite such Shareholders to apply in writing for the balance of the Sale Shares (being those Sale Shares for which the Ordinary Shareholders have not applied).
- 17.6.3 If the Sale Shares are subject to a Minimum Transfer Condition then any allocation made under Article 17.7 will be conditional on the fulfilment of the Minimum Transfer Condition.

# 17.6.4 If:

(a) at the end of the First Offer Period, the number of Sale Shares applied for is equal to or exceeds the number of Sale Shares on offer, the Board shall allocate the Sale Shares to each Series B Shareholder and Series A Shareholder who has applied for them (the Series B Applying Shareholders and Series A Applying Shareholders, respectively) pro rata to its respective holding of Series B Shares (calculated as a proportion of the total number of Series B Shares held by Series B Applying Shareholders) and Series A Shares (calculated as a proportion of the total number of Series A Shares held by Series A Applying Shareholders) until all the Sale Shares have been allocated (as nearly as may be without involving fractions);

- (b) at the end of the Second Offer Period, the number of Sale Shares applied for is equal to or exceeds the number of Sale Shares on offer, the Board shall allocate the Sale Shares to those Shareholders who have applied for them (the **Applying Shareholders**) in the order of priority set out in Article 17.6.1 and pro rata to each Shareholder's respective holding of Series B Shares and Series A Shares (for the purposes of Article 17.6.1(a)) or Ordinary Shares (for the purposes of Article 17.6.1(b)), in each case, calculated as a proportion of the relevant class of Shares held by Applying Shareholders, until all Sale Shares have been allocated (as nearly as may be without involving fractions);
- (c) at the end of the Third Offer Period, the number of Sale Shares applied for is equal to or exceeds the number of Sale Shares on offer, the Board shall allocate the Sale Shares to those Shareholders who have applied for them in the order of priority set out in Article 17.6.1 and pro rata to each Shareholder's respective holding of Series B Shares and Series A Shares (for the purposes of Article 17.6.1(a)), Ordinary Shares (for the purposes of Article 17.6.1(b)) or Series B Shares (for the purposes of Article 17.6.1(c)), in each case, calculated as a proportion of the relevant class of Shares held by Applying Shareholders, until all New Securities have been allotted (as nearly as may be without involving fractions),

save that, in each case, no allocation shall be made to a Shareholder of more than the maximum number of Sale Shares that it has stated it is willing to buy.

- 17.6.5 If, at the end of the Third Offer Period, the number of Sale Shares applied for is less than the number of Sale Shares on offer or there remain any Sale Shares that are not capable of being allocated between Applying Shareholders except by way of fractions, the balance of any Sale Shares will be dealt with in accordance with Article 17.7.5.
- 17.7 Completion of transfer of Sale Shares
- 17.7.1 If the Transfer Notice includes a Minimum Transfer Condition and the total number of Shares applied for does not meet the Minimum Transfer Condition the Board shall notify the Seller and all those to whom Sale Shares have been conditionally allocated under Article 17.6 stating the condition has not been met and that the relevant Transfer Notice has lapsed with immediate effect.
- 17.7.2 lf:
  - (a) the Transfer Notice does not include a Minimum Transfer Condition; or
  - (b) the Transfer Notice does include a Minimum Transfer Condition and allocations have been made in respect of all or the minimum required number of the Sale Shares,

the Board shall, when no further offers are required to be made under Article 17.6 and once the requirements of Articles 19 and/or 20 have been fulfilled to the extent required, give written notice of allocation (an **Allocation Notice**) to the Seller and each Shareholder to whom Sale Shares have been allocated (an **Applicant**) specifying the number of Sale Shares allocated to each Applicant and the place and time (being not less than 10 Business Days nor more than 20 Business Days after the date of the Allocation Notice) for completion of the transfer of the Sale Shares.

- 17.7.3 Upon service of an Allocation Notice, the Seller must, against payment of the Transfer Price, transfer the Sale Shares in accordance with the requirements specified in it.
- 17.7.4 If the Seller fails to comply with the provisions of Article 17.7.3:
  - (a) the chairman of the Company or, failing him, one of the Directors, or some other person nominated by a resolution of the Board, may on behalf of the Seller:
    - complete, execute and deliver in his name all documents necessary to give effect to the transfer of the relevant Sale Shares to the Applicants;
    - (ii) receive the Transfer Price and give a good discharge for it; and
    - (iii) (subject to the transfer being duly stamped) enter the Applicants in the register of Shareholders as the holders of the Shares purchased by them; and
  - (b) the Company shall pay the Transfer Price into a separate bank account in the Company's name on trust (but without interest) or otherwise hold the Transfer Price on trust for the Seller until he has delivered to the Company his certificate or certificates for the relevant Shares (or an indemnity for lost certificate in a form acceptable to the Board).
- 17.7.5 If an Allocation Notice does not relate to all the Sale Shares then, subject to Article 17.7.6, the Seller may, within eight weeks after service of the Allocation Notice, transfer the unallocated Sale Shares to any person at a price at least equal to the Transfer Price.
- 17.7.6 The right of the Seller to transfer Shares under Article 17.7.5 does not apply if the Board is of the opinion on reasonable grounds that:
  - (a) the transferee is a person (or a nominee for a person) who the Board determines in its absolute discretion is a competitor with (or an Associate of a competitor with) the business of the Company or with a Subsidiary Undertaking of the Company;
  - (b) the sale of the Sale Shares is not bona fide or the price is subject to a deduction, rebate or allowance to the transferee; or
  - (c) the Seller has failed or refused to provide promptly information available to it or him and reasonably requested by the Board for the purpose of enabling it to form the opinion mentioned above.

- 17.8 Any Sale Shares offered under this Article 17 to a holder of Equity Shares may be accepted in full or part only by a Permitted Transferee of such holder of Equity Shares in accordance with the terms of this Article 17.
- 17.9 The holders of Ordinary Shares, Series A Shares and Series B Shares may waive their respective rights under this Article 17 with the consent in writing of the holders of more than 75 per cent. in nominal value of the issued shares of that class (in which case such waiver shall be binding on the entire class).

#### 18. VALUATION OF SHARES

- 18.1 If no Transfer Price can be agreed between the Seller and the Board in accordance with provisions of Articles 15.9(a) or 17.2 or otherwise then, on the date of failing agreement, the Board shall either:
  - (a) appoint an expert valuer in accordance with Article 18.2 (the **Expert Valuer**) to certify the Fair Value of the Sale Shares; or
  - (b) (if the Fair Value has been certified by an Expert Valuer within the preceding 12 weeks) specify that the Fair Value of the Sale Shares will be calculated by dividing any Fair Value so certified by the number of Sale Shares to which it related and multiplying such Fair Value by the number of Sale Shares that are the subject of the Transfer Notice.
- 18.2 The Expert Valuer will be either:
  - (a) the Auditors; or
  - (b) (if otherwise agreed by the Board and the Seller) an independent firm of chartered accountants to be agreed between the Board and the Seller or failing agreement not later than the date 10 Business Days after the date of service of the Transfer Notice to be nominated by the then President of the Institute of Chartered Accountants in England and Wales on the application of either party and approved by the Company.
- The **Fair Value** of the Sale Shares shall be determined by the Expert Valuer on the following assumptions and bases:
  - (a) valuing the Sale Shares as on an arm's-length sale between a willing seller and a willing buyer;
  - (b) if the Company is then carrying on business as a going concern, on the assumption that it will continue to do so;
  - (c) that the Sale Shares are capable of being transferred without restriction;
  - (d) valuing the Sale Shares as a rateable proportion of the total value of all the issued Shares (excluding any Shares held as Treasury Shares) without any premium or discount being attributable to the percentage of the issued share capital of the Company which they represent but taking account of the rights attaching to the Sale Shares; and

- (e) reflect any other factors which the Expert Valuer reasonably believes should be taken into account.
- 18.4 If any difficulty arises in applying any of these assumptions or bases then the Expert Valuer shall resolve that difficulty in whatever manner they shall in their absolute discretion think fit.
- The Expert Valuer shall be requested to determine the Fair Value within 20 Business Days of their appointment and to notify the Board of their determination.
- The Expert Valuer shall act as experts and not as arbitrators and their determination shall be final and binding on the parties (in the absence of fraud or manifest error).
- 18.7 The Board will give the Expert Valuer access to all accounting records or other relevant documents of the Company subject to them agreeing to such confidentiality provisions as the Board may reasonably impose.
- The Expert Valuer shall deliver their certificate to the Company. As soon as the Company receives the certificate it shall deliver a copy of it to the Seller. Unless the Sale Shares are to be sold under a Transfer Notice, which is deemed to have been served, the Seller may by notice in writing to the Company within five Business Days of the service on him of the copy certificate, cancel the Company's authority to sell the Sale Shares.
- 18.9 The cost of obtaining the certificate shall be paid by the Company unless:
  - (a) the Seller cancels the Company's authority to sell; or
  - (b) the Transfer Price certified by the Expert Valuer is less than the price (if any) offered by the Directors to the Seller for the Sale Shares before the Expert Valuer was instructed,

in which case the Seller shall bear the cost.

# 19. COMPULSORY TRANSFERS — GENERAL

- 19.1 A person entitled to a Share in consequence of the bankruptcy of a Shareholder shall be deemed to have given a Transfer Notice in respect of that Share at a time determined by the Directors.
- 19.2 If a Share remains registered in the name of a deceased Shareholder for longer than one year after the date of his death the Directors may require the legal personal representatives of that deceased Shareholder either:
  - (a) to effect a Permitted Transfer of such Shares (including for this purpose an election to be registered in respect of the Permitted Transfer); or
  - (b) to show to the satisfaction of the Directors that a Permitted Transfer will be effected before or promptly upon the completion of the administration of the estate of the deceased Shareholder.

If either requirement in this Article 19.2 shall not be fulfilled to the satisfaction of the Directors a Transfer Notice shall be deemed to have been given in respect of each such Share save to the extent that, the Directors may otherwise determine.

- 19.3 If a Shareholder which is a company, either suffers or resolves for the appointment of a liquidator, administrator or administrative receiver over it or any material part of its assets (other than as part of a bona fide restructuring or reorganisation), the relevant Shareholder (and all its Permitted Transferees) shall be deemed to have given a Transfer Notice in respect of all the shares held by the relevant Shareholder and its Permitted Transferees save to the extent, and at a time, that the Directors may determine.
- 19.4 If there is a change in control (as control is defined in section 1124 of the CTA 2010) of any Shareholder which is a company, it shall be bound at any time, if and when required in writing by the Directors to do so, to give (or procure the giving in the case of a nominee) a Transfer Notice in respect of all the Shares registered in its and their names and their respective nominees' names save that, in the case of the Permitted Transferee, it shall first be permitted to transfer those Shares back to the Original Shareholder from whom it received its Shares or to any other Permitted Transferee before being required to serve a Transfer Notice. This Article 19.4 shall not apply to a Shareholder that is an Investor.

#### 20. MANDATORY OFFER ON A CHANGE OF CONTROL

- 20.1 Except in the case of Permitted Transfers and transfers pursuant to Article 19, after going through the pre-emption procedure in Article 17, the provisions of Article 20.2 will apply if one or more Proposed Sellers propose to transfer in one or a series of related transactions any Equity Shares (the **Proposed Transfer**) which would, if put into effect, result in any Proposed Purchaser (and Associates of his or persons Acting in Concert with him) acquiring a Controlling Interest in the Company.
- A Proposed Seller must, before making a Proposed Transfer procure the making by the Proposed Purchaser of an offer (the **Offer**) to the other Shareholders to acquire all of the Equity Shares and the G Shares for a consideration per share the value of which is at least equal to the Specified Price (as defined in Article 20.7).
- 20.3 The Offer must be given by written notice (a **Proposed Sale Notice**) at least 20 Business Days (the **Offer Period**) prior to the proposed sale date (**Proposed Sale Date**). The Proposed Sale Notice must set out, to the extent not described in any accompanying documents, the identity of the Proposed Purchaser, the purchase price and other terms and conditions of payment, the Proposed Sale Date and the number of Shares proposed to be purchased by the Proposed Purchaser (the **Proposed Sale Shares**).
- 20.4 If any other holder of Equity Shares or G Shares is not given the rights accorded him by this Article 20, the Proposed Sellers will not be entitled to complete their sale and the Company will not register any transfer intended to carry that sale into effect.
- 20.5 If the Offer is accepted by any Shareholder (an **Accepting Shareholder**) within the Offer Period, the completion of the Proposed Transfer will be conditional upon the completion of the purchase of all the Shares held by Accepting Shareholders.

- The Proposed Transfer is subject to the pre-emption provisions of Article 17 but the purchase of the Accepting Shareholders' shares shall not be subject to Article 17.
- 20.7 For the purpose of this Article 20:
  - (a) the expression Specified Price shall mean in respect of each Share a sum in cash equal to the highest price per Share offered or paid by the Proposed Purchaser:
    - (i) in the Proposed Transfer; or
    - (ii) in any related or previous transaction by the Proposed Purchaser or any person Acting in Concert with the Proposed Purchaser in the 12 months preceding the date of the Proposed Transfer,

plus an amount equal to the Relevant Sum, as defined in Article 20.7(b), of any other consideration (in cash or otherwise) paid or payable by the Proposed Purchaser or any other person Acting in Concert with the Proposed Purchaser, which having regard to the substance of the transaction as a whole, can reasonably be regarded as an addition to the price paid or payable for the Shares (the **Supplemental Consideration**) provided that the total consideration paid by the Proposed Purchaser in respect of the Proposed Transfer is distributed to the Proposed Seller and the Accepting Shareholders in accordance with the provisions of Articles 5 and 6;

(b) "Relevant Sum" = C ÷ A

where: A = number of Equity Shares being sold in connection with the relevant Proposed Transfer; and

C = the Supplemental Consideration.

# 21. DRAG-ALONG

- If a Series B Majority and a Series A Majority (together the Selling Shareholders) wish to transfer all their interest in Shares (the Sellers' Shares) to a Proposed Purchaser approved by the Board, the Selling Shareholders shall have the option (the Drag Along Option) to compel each other holder of Shares (each a Called Shareholder and together the Called Shareholders) to sell and transfer all their Shares to the Proposed Purchaser or as the Proposed Purchaser shall direct (the Drag Purchaser) in accordance with the provisions of this Article.
- 21.2 The Selling Shareholders may exercise the Drag Along Option by giving a written notice to that effect (a **Drag Along Notice**) to the Company which the Company shall forthwith copy to the Called Shareholders at any time before the transfer of the Sellers' Shares to the Drag Purchaser. A Drag Along Notice shall specify that:
  - (a) the Called Shareholders are required to transfer all their Shares (the **Called Shares**) under this Article 21;
  - (b) the person to whom they are to be transferred;

- (c) the consideration for which the Called Shares are to be transferred (calculated in accordance with this Article 21);
- (d) the proposed date of transfer; and
- (e) the form of any sale agreement or form of acceptance or any other document of similar effect (if any) that the Called Shareholders are required to sign in connection with such sale (the Sale Agreement),

(and, in the case of paragraphs (b) to (d) above, whether actually specified or to be determined in accordance with a mechanism described in the Drag Along Notice). No Drag Along Notice or Sale Agreement may either (i) require an Investor to give warranties, covenants, or indemnities (except a warranty as to title to the shares held by such Investor); or (ii) require a Called Shareholder to agree to any terms except those specifically provided for in this Article.

- 21.3 Drag Along Notices shall be irrevocable but will lapse if for any reason there is not a sale of the Sellers' Shares by the Selling Shareholders to the Drag Purchaser within 60 Business Days after the date of service of the Drag Along Notice. The Selling Shareholders shall be entitled to serve further Drag Along Notices following the lapse of any particular Drag Along Notice.
- 21.4 The consideration (in cash or otherwise) for which the Called Shareholders shall be obliged to sell each of the Called Shares shall be that to which they would be entitled if the total consideration proposed to be paid by the Drag Purchaser were distributed to the holders of the Called Shares and the Sellers' Shares in accordance with the provisions of Articles 5 and 6 (the **Drag Consideration**).
- 21.5 Within three Business Days of the Company copying the Drag Along Notice to the Called Shareholders (or such later date as may be specified in the Drag Along Notice) (the **Drag Completion Date**), each Called Shareholder shall deliver:
  - (a) duly executed stock transfer form(s) for its Shares in favour of the Drag Purchaser;
  - (b) the relevant share certificate(s) (or a duly executed indemnity for lost certificate in a form acceptable to the Board) to the Company; and
  - (c) duly executed Sale Agreement, if applicable, in the form specified in the Drag Along Notice or as otherwise specified by the Company,

(together the Drag Documents).

- On the Drag Completion Date, the Company shall pay each Called Shareholder, on behalf of the Drag Purchaser, the Drag Consideration that is due to the extent the Drag Purchaser has paid such consideration to the Company. The Company's receipt of the Drag Consideration shall be a good discharge to the Drag Purchaser. The Company shall hold the Drag Consideration in trust for each of the Called Shareholders without any obligation to pay interest.
- 21.7 To the extent that the Drag Purchaser has not, on the Drag Completion Date, paid the Drag Consideration that is due to the Company, the Called Shareholders shall

be entitled to the immediate return of the Drag Documents for the relevant Shares and the Called Shareholders shall have no further rights or obligations under this Article 21 in respect of their Shares.

- 21.8 If a Called Shareholder fails to deliver the Drag Documents for its Shares to the Company by the Drag Completion Date, the Company and each Director shall be constituted the agent of such defaulting Called Shareholder to take such actions and enter into any Drag Document or such other agreements or documents as are necessary to effect the transfer of the Called Shareholder's Shares pursuant to this Article 21 and the Directors shall, if requested by the Drag Purchaser, authorise any Director to transfer the Called Shareholder's Shares on the Called Shareholder's behalf to the Drag Purchaser to the extent the Drag Purchaser has, by the Drag Completion Date, paid the Drag Consideration to the Company for the Called Shareholder's Shares offered to him. The Board shall then authorise registration of the transfer once appropriate stamp duty has been paid. The defaulting Called Shareholder shall surrender his share certificate for his Shares (or suitable executed indemnity) to the Company. On surrender, he shall be entitled to the Drag Consideration due to him.
- 21.9 Any transfer of Shares to a Drag Purchaser pursuant to a sale in respect of which a Drag Along Notice has been duly served shall not be subject to the provisions of Article 17.
- 21.10 On any person, following the issue of a Drag Along Notice, becoming a Shareholder pursuant to the exercise of a pre-existing option or warrant to acquire shares in the Company or pursuant to the conversion of any convertible security of the Company (a **New Shareholder**), a Drag Along Notice shall be deemed to have been served on the New Shareholder on the same terms as the previous Drag Along Notice who shall then be bound to sell and transfer all Shares so acquired to the Drag Purchaser and the provisions of this Article 21 shall apply with the necessary changes to the New Shareholder except that completion of the sale of the Shares shall take place immediately on the Drag Along Notice being deemed served on the New Shareholder.

## 22. GENERAL MEETINGS

- 22.1 If the Directors are required by the Shareholders under section 303 of the Act to call a general meeting, the Directors shall convene the meeting for a date not later than 28 days after the date on which the Directors became subject to the requirement under section 303 of the Act.
- The provisions of section 318 of the Act shall apply to the Company, save that if a quorum is not present at any meeting adjourned for the reason referred to in Article 41 of the Model Articles, then, provided that the Qualifying Person present holds or represents the holder of at least two thirds in nominal value of the Equity Shares (excluding Treasury Shares), any resolution agreed to by such Qualifying Person shall be as valid and effectual as if it had been passed unanimously at a general meeting of the Company duly convened and held.

- 22.3 If any two or more Shareholders (or Qualifying Persons representing two or more Shareholders) attend the meeting in different locations, the meeting shall be treated as being held at the location specified in the notice of the meeting, save that if no one is present at that location so specified, the meeting shall be deemed to take place where the largest number of Qualifying Persons is assembled or, if no such group can be identified, at the location of the chairman.
- 22.4 If a demand for a poll is withdrawn under Article 44(3) of the Model Articles, the demand shall not be taken to have invalidated the result of a show of hands declared before the demand was made and the meeting shall continue as if the demand had not been made.
- Polls must be taken in such manner as the chairman directs. A poll demanded on the election of a chairman or on a question of adjournment must be held immediately. A poll demanded on any other question must be held either immediately or at such time and place as the chairman directs not being more than 14 days after the poll is demanded. The demand for a poll shall not prevent the continuance of a meeting for the transaction of any business other than the question on which the poll was demanded.
- No notice need be given of a poll not held immediately if the time and place at which it is to be taken are announced at the meeting at which it is demanded. In any other case at least seven clear days' notice shall be given specifying the time and place at which the poll is to be taken.
- 22.7 If the poll is to be held more than 48 hours after it was demanded the Shareholders shall be entitled to deliver proxy notices in respect of the poll at any time up to 24 hours before the time appointed for taking that poll. In calculating that period, no account shall be taken of any part of a day that is not a working day.

# 23. PROXIES

- 23.1 Paragraph (c) of Article 45(1) of the Model Articles shall be deleted and replaced by the words: "is signed by or on behalf of the shareholder appointing the proxy and accompanied by any the authority under which it is signed (or a certified copy of such authority or a copy of such authority in some other way approved by the directors)".
- The instrument appointing a proxy and any authority under which it is signed or a certified copy of such authority or a copy in some other way approved by the Directors may:
  - (a) be sent or supplied in hard copy form, or (subject to any conditions and limitations which the Board may specify) in electronic form, to the registered office of the Company or to such other address (including electronic address) as may be specified for this purpose in the notice convening the meeting or in any instrument of proxy or any invitation to appoint a proxy sent or supplied by the Company in relation to the meeting at any time before the time for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote;

- (b) be delivered at the meeting or adjourned meeting at which the person named in the instrument proposes to vote to the chairman or to the company secretary or to any Director; or
- (c) in the case of a poll, be delivered at the meeting at which the poll was demanded to the chairman or to the company secretary or to any Director, or at the time and place at which the poll is held to the Chairman or to the company secretary or to any Director or scrutineer,

and an instrument of proxy which is not deposited or delivered in a manner so permitted shall be invalid.

## 24. DIRECTORS' BORROWING POWERS

The Directors may, where required, exercise all the powers of the Company to borrow or raise money and to mortgage or charge its undertaking, property and uncalled capital and to issue debentures, debenture stock and other securities as security for any debt, liability or obligation of the Company or of any third party.

# 25. ALTERNATE DIRECTORS

- 25.1 Notwithstanding any provision of these Articles to the contrary, any person appointed as a Director (the **Appointor**) may appoint any Director or any other person as he thinks fit to be his alternate Director to:
  - (a) exercise that Director's powers; and
  - (b) carry out that Director's responsibilities in relation to the taking of decisions by the Directors in the absence of the alternate's Appointor.

The appointment of an alternate Director shall not require approval by a resolution of the Directors.

- 25.2 Any appointment or removal of an alternate must be effected by notice in writing to the Company signed by the Appointor, or in any other manner approved by the Directors.
- 25.3 The notice must:
  - (a) identify the proposed alternate; and
  - (b) in the case of a notice of appointment, contain a statement signed by the proposed alternate that the proposed alternate is willing to act as the alternate of the Director giving the notice.
- An alternate Director may act as an alternate to more than one Director and has the same rights, in relation to any Directors' meeting (including as to notice) or Directors' written resolution, as the alternate's Appointor.
- 25.5 Except as these Articles specify otherwise, alternate directors:
  - (a) are deemed for all purposes to be Directors;
  - (b) are liable for their own acts and omissions;

- (c) are subject to the same restrictions as their Appointors; and
- (d) are not deemed to be agents of or for their Appointors,

and, in particular (without limitation), each alternate Director shall be entitled to receive notice of all meetings of Directors and of all meetings of committees of Directors of which his Appointor is a member.

- 25.6 A person who is an alternate Director but not a Director:
  - (a) may be counted as participating for the purposes of determining whether a quorum is participating (but only if that person's Appointor is not participating);
     and
  - (b) may sign a Directors' written resolution (but only if his Appointor is an Eligible Director in relation to that decision, but does not participate).

No alternate may be counted as more than one Director for such purposes.

- A Director who is also an alternate Director is entitled, in the absence of his Appointor, to a separate vote on behalf of each Appointor, in addition to his own vote on any decision of the Directors (provided that his Appointor is an Eligible Director in relation to that decision).
- An alternate Director is not entitled to receive any remuneration from the Company for serving as an alternate Director, except such part of the alternate's Appointor's remuneration as the Appointor may direct by notice in writing made to the Company.
- 25.9 An alternate Director's appointment as an alternate shall terminate:
  - (a) when the alternate's Appointor revokes the appointment by notice to the Company in writing specifying when it is to terminate;
  - (b) on the occurrence in relation to the alternate of any event which, if it occurred in relation to the alternate's Appointor, would result in the termination of the Appointor's appointment as a Director;
  - (c) on the death of the alternate's Appointor; or
  - (d) when the alternate's Appointor's appointment as a Director terminates.

# 26. NUMBER OF DIRECTORS

Unless and until the Company shall otherwise determine by ordinary resolution, the number of Directors shall not exceed nine but shall not be not less than two.

## 27. APPOINTMENT OF DIRECTORS

- 27.1 In addition to the powers of appointment under Article 17(1) of the Model Articles:
  - (a) subject to Article 27.6, for so long as the Series A Investors together hold at least 10 per cent. of the total issued share capital of the Company, they shall (by notice in writing from a Series A Majority to the Company) be entitled to appoint (and remove and reappoint) one natural person as non-executive director (other than the Chairman Director) to the Board (the Series A

**Investor Director**), subject to approval of the nominee Series A Investor Director by (i) the Board and (ii) the Chairman Director (such approval, in each case, not to be unreasonably withheld or delayed) and the other holders of Shares shall not vote their Shares so as to remove that Director from office;

- (b) subject to Article 27.6, for so long as Lilly holds at least 7 per cent. of the total issued share capital of the Company and such holding includes at least one Series B Share, it shall be entitled to appoint (and remove and reappoint) one natural person as non-executive director (other than the Chairman Director) to the Board (the Lilly Director), subject to approval of the nominee Lilly Director by (i) the Board and (ii) the Chairman Director (such approval, in each case, not to be unreasonably withheld or delayed) and the other holders of Shares shall not vote their Shares so as to remove that Director from office;
- (c) subject to Article 27.6, for so long as General Atlantic holds:
  - (i) at least 75 per cent. of the Initial GA Holding, General Atlantic shall (by notice in writing) be entitled to appoint (and remove and reappoint) up to two natural persons as non-executive directors (other than the Chairman Director) to the Board (each a GA Investor Director and together the GA Investor Directors); or
  - (ii) at least 50 per cent. (but less than 75 per cent.) of the Initial GA Holding, General Atlantic shall (by notice in writing) be entitled to appoint (and remove and reappoint) one GA Investor Director to the Board,

in each case, subject to approval of any nominee GA Investor Director by the Board (such approval not to be unreasonably withheld or delayed) and the other holders of Shares shall not vote their Shares so as to remove that Director from office:

- (d) subject to Article 27.6, for so long as any Series B Shareholder (other than General Atlantic, Lilly and the Foundation) holds at least 5 per cent. of the total issued share capital of the Company, that Series B Shareholder (an **Appointing Series B Investor**) shall (by notice in writing) be entitled to appoint (and remove and reappoint) one natural person as non-executive director (other than the Chairman Director) to the Board (a **Series B Investor Director**), subject to approval of any nominee Series B Investor Director by the (i) Board; (ii) the Chairman Director and (iii) General Atlantic (for so long as there is at least one GA Investor Director on the Board) and provided that, if there is more than one Appointing Series B Investor, the right to appoint a Series B Investor Director pursuant to this Article 27.1(d) shall be exercisable by those Appointing Series B Investors acting jointly;
- (e) the Board, acting by majority vote (excluding any existing Chairman Director), shall have the right to nominate one natural person to act as Director and Chairman of the Board (the Chairman Director), and may remove and replace such Chairman Director, provided that the Chairman Director shall be subject to annual re-election by majority vote (excluding the Chairman Director), subject, in each case, to General Atlantic approval of any nominee

- Chairman Director (for so long as there is at least one GA Investor Director on the Board) (such approval not to be unreasonably withheld or delayed);
- (f) the Board, acting by majority vote (excluding any existing CEO Director), shall have the right to nominate one natural person to act as Director and CEO of the Board (the CEO Director), and may remove and replace such CEO Director; and
- (g) the Board, acting by majority vote, shall have the right to nominate and appoint up to two natural persons (excluding any Investor Directors) to act as independent Directors (each an Independent Director and together the Independent Directors), and may remove and replace such Independent Director, subject to approval of any nominee Independent Director by (i) the Chairman Director and (ii) General Atlantic (for so long as there is at least one GA Investor Director on the Board) (such approval, in each case, not to be unreasonably withheld or delayed).
- An appointment or removal of a Director under Article 27.1 will take effect at and from the time when the notice is received at the registered office of the Company or produced to a meeting of the Directors of the Company.
- 27.3 Each Director appointed pursuant to Article 27.1 shall be entitled at his request to be appointed to any committee of the Board established from time to time.
- For so long as it holds Shares, the Foundation shall have the right to appoint a representative to attend as an observer at each meeting of the Board held in each calendar year, who will be entitled to speak at any such meetings but will not be entitled to vote.
- 27.5 The Company shall conduct a review of its Board composition by 13 August 2020 with a view to ensuring that (among other things) the Board has appropriate public company experience (the **Board Review**). The Shareholders hereby agree to provide all such co-operation and consents as are required pursuant to these Articles or otherwise to facilitate any proposed changes to the Board composition (as agreed by the Board, acting by majority vote) promptly upon completion of the Board Review.
- Upon an IPO, (i) the respective rights of (a) Lilly; (b) the Series A Investors; and (c) the Appointing Series B Investor, to appoint the Lilly Director, the Series A Investor Director, and the Series B Investor Director respectively shall terminate and cease to have effect, and (ii) the right of GA to appoint the GA Investor Directors will terminate and cease to have effect if required under applicable law, rule or regulation (including any applicable criteria on the independence, experience and expertise of the GA Investor Directors) or if requested by the Company's lead underwriter at such time. To the extent required by the preceding sentence, each such Investor or Investors respectively shall procure, in so far as it is legally possible to do so, that the Lilly Director, the Series A Investor Director, the GA Investor Directors, and the Series B Investor Director (as applicable) resign immediately prior to the IPO without seeking compensation for loss of office and waiving all claims that such Director (as applicable) may have against the Company in connection

thereto. If any such Director (as applicable) refuses to resign pursuant to this Article 27.6, then the parties agree that the Board, acting by majority vote (excluding any such refusing Director (as applicable)) shall be entitled to remove such Director or Directors (as applicable).

27.7 If the Lilly Director is required to resign from the Board as part of any proposed changes to the Board composition agreed at the Board Review (as agreed by the Board, acting by majority vote), then, with effect from the date of such resignation and for so long as Lilly holds at least 7 per cent. of the total issued share capital of the Company and such holding includes at least one Series B Share, Lilly shall have the right to appoint a representative to attend as an observer at each meeting of the Board held in each calendar year, who will be entitled to speak at any such meetings but will not be entitled to vote.

# 28. DISQUALIFICATION OF DIRECTORS

In addition to that provided in Article 18 of the Model Articles, the office of a Director shall also be vacated if:

- (a) he is convicted of a criminal offence (other than a minor motoring offence) and the Directors resolve that his office be vacated; or
- (b) in the case of Directors other than an Investor Director, if a majority of his co-Directors serve notice on him in writing, removing him from office.

### 29. PROCEEDINGS OF DIRECTORS

- 29.1 The quorum for Directors' meetings shall be three Directors, including at least one GA Investor Director or its alternate (for so long as there is a GA Investor Director on the Board) and at least one Series A Investor Director or its alternate (for so long as there is a Series A Investor Director on the Board), save that:
  - (a) where a Relevant Interest of an Investor Director is being authorised by other Directors in accordance with section 175(5)(a) of the Act, such Investor Director and any other interested Director shall not be included in the quorum required for the purpose of such authorisation but shall otherwise be included for the purpose of forming the quorum at the meeting; and
  - (b) where no Series A Investor Director has attended or been represented by an alternate at the previous Board meeting, the meeting shall be quorate if at least three Directors, including at least one GA Investor Director or its alternate (for so long as there is a GA Investor Director on the Board), are present or represented by an alternate,

and if such a quorum is not present within half an hour from the time appointed for the meeting, or if during a meeting such quorum ceases to be present, the meeting shall stand adjourned to the same day in the next week at the same time and place or at such time and place as determined by the Directors present at such meeting. If a quorum is not present at any such adjourned meeting within half an hour from the time appointed, then the meeting shall proceed.

- In the event that a meeting of the Directors is attended by a Director who is acting as alternate for one or more other Directors, the Director or Directors for whom he is the alternate shall be counted in the quorum despite their absence, and if on that basis there is a quorum the meeting may be held despite the fact (if it is the case) that only one Director is physically present.
- 29.3 If all the Directors participating in a meeting of the Directors are not physically in the same place, the meeting shall be deemed to take place where the largest group of participators in number is assembled. In the absence of a majority the location of the chairman shall be deemed to be the place of the meeting.
- 29.4 Notice of a Directors' meeting need not be given to Directors who waive their entitlement to notice of that meeting, by giving notice to that effect to the Company at any time before or after the date on which the meeting is held. Where such notice is given after the meeting has been held, that does not affect the validity of the meeting, or of any business conducted at it.
- Provided (if these Articles so require) that he has declared to the Directors, in accordance with the provisions of these Articles, the nature and extent of his interest (and subject to any restrictions on voting or counting in a quorum imposed by the Directors in authorising a Relevant Interest), a Director may vote at a meeting of the Directors or of a committee of the Directors on any resolution concerning a matter in which he has an interest, whether a direct or an indirect interest, or in relation to which he has a duty and shall also be counted in reckoning whether a quorum is present at such a meeting.
- Questions arising at any meeting of the Directors shall be decided by a majority of votes. In the case of any equality of votes, the chairman shall not have a second or casting vote.
- 29.7 A decision of the Directors may take the form of a resolution in writing, where each Eligible Director has signed one or more copies of it, or to which each Eligible Director has otherwise indicated agreement in writing (including confirmation given by electronic means). Reference in Article 7(1) of the Model Articles to Article 8 of the Model Articles shall be deemed to include a reference to this Article 29 also.

# 30. DIRECTORS' INTERESTS

Specific interests of a Director

- 30.1 Subject to the provisions of the Act and provided (if these Articles so require) that he has declared to the Directors in accordance with the provisions of these Articles, the nature and extent of his interest, a Director may (save as to the extent not permitted by law from time to time), notwithstanding his office, have an interest of the following kind:
  - (a) where a Director (or a person connected with him) is party to or in any way directly or indirectly interested in, or has any duty in respect of, any existing or proposed contract, arrangement or transaction with the Company or any other undertaking in which the Company is in any way interested;

- (b) where a Director (or a person connected with him) is a director, employee or other officer of, or a party to any contract, arrangement or transaction with, or in any way interested in, any body corporate promoted by the Company or in which the Company is in any way interested;
- (c) where a Director (or a person connected with him) is a shareholder in the Company or a shareholder in, employee, director, member or other officer of, or consultant to, a Parent Undertaking of, or a Subsidiary Undertaking of a Parent Undertaking of, the Company;
- (d) where a Director (or a person connected with him) holds and is remunerated in respect of any office or place of profit (other than the office of auditor) in respect of the Company or body corporate in which the Company is in any way interested;
- (e) where a Director is given a guarantee, or is to be given a guarantee, in respect of an obligation incurred by or on behalf of the Company or any body corporate in which the Company is in any way interested;
- (f) where a Director (or a person connected with him or of which he is a member or employee) acts (or any body corporate promoted by the Company or in which the Company is in any way interested of which he is a director, employee or other officer may act) in a professional capacity for the Company or any body corporate promoted by the Company or in which the Company is in any way interested (other than as auditor) whether or not he or it is remunerated for this;
- (g) an interest which cannot reasonably be regarded as likely to give rise to a conflict of interest; or
- (h) any other interest authorised by ordinary resolution.

### Interests of an Investor Director

- In addition to the provisions of Article 30.1, subject to the provisions of the Act and provided (if these Articles so require) that he has declared to the Directors in accordance with the provisions of these Articles, the nature and extent of his interest, where a Director is an Investor Director he may (save as to the extent not permitted by law from time to time), notwithstanding his office, have an interest arising from any duty he may owe to, or interest he may have as an employee, director, trustee, member, partner, officer or representative of, or a consultant to, or direct or indirect investor (including without limitation by virtue of a carried interest, remuneration or incentive arrangements or the holding of securities) in:
  - (a) an Investor;
  - (b) a Fund Manager which advises or manages an Investor;
  - any of the funds advised or managed by a Fund Manager who advises or manages an Investor from time to time; or

(d) another body corporate or firm in which a Fund Manager who advises or manages an Investor or any fund advised or managed by such Fund Manager has directly or indirectly invested, including without limitation any portfolio companies.

Interests of which a Director is not aware

30.3 For the purposes of this Article 30, an interest of which a Director is not aware and of which it is unreasonable to expect him to be aware shall not be treated as an interest of his.

Accountability of any benefit and validity of a contract

In any situation permitted by this Article 30 (save as otherwise agreed by him) a Director shall not by reason of his office be accountable to the Company for any benefit which he derives from that situation and no such contract, arrangement or transaction shall be avoided on the grounds of any such interest or benefit.

Terms and conditions of Board authorisation

- 30.5 Subject to Article 30.6, any authority given in accordance with section 175(5)(a) of the Act in respect of a Director (Interested Director) who has proposed that the Directors authorise his interest (Relevant Interest) pursuant to that section may, for the avoidance of doubt:
  - (a) be given on such terms and subject to such conditions or limitations as may be imposed by the authorising Directors as they see fit from time to time, including, without limitation:

restricting the Interested Director from voting on any resolution put to a meeting of the Directors or of a committee of the Directors in relation to the Relevant Interest:

- restricting the Interested Director from being counted in the quorum at a meeting of the Directors or of a committee of the Directors where such Relevant Interest is to be discussed; or
- (ii) restricting the application of the provisions in Articles 29.7 and 29.8 so far as is permitted by law, in respect of such Interested Director;
- (b) be withdrawn, or varied at any time by the Directors entitled to authorise the Relevant Interest as they see fit from time to time; and

subject to Article 30.6, an Interested Director must act in accordance with any such terms, conditions or limitations imposed by the authorising Directors pursuant to section 175(5)(a) of the Act and this Article 30.

Terms and conditions of Board authorisation for an Investor Director

30.6 Notwithstanding the other provisions of this Article 30, it shall not (save with the consent in writing of an Investor Director) be made a condition of any authorisation of a matter in relation to that Investor Director in accordance with section 175(5)(a) of the Act, that he shall be restricted from voting or counting in the quorum at any

meeting of, or of any committee of the Directors or that he shall be required to disclose, use or apply confidential information as contemplated in Article 30.8.

Director's duty of confidentiality to a person other than the Company

- 30.7 Subject to Article 30.8 (and without prejudice to any equitable principle or rule of law which may excuse or release the Director from disclosing information, in circumstances where disclosure may otherwise be required under this Article 31), if a Director, otherwise than by virtue of his position as Director, receives information in respect of which he owes a duty of confidentiality to a person other than the Company, he shall not be required:
  - (a) to disclose such information to the Company or to any Director, or to any officer or employee of the Company; or
  - (b) otherwise to use or apply such confidential information for the purpose of or in connection with the performance of his duties as a Director.
- Where such duty of confidentiality arises out of a situation in which a Director has, or can have, a direct or indirect interest that conflicts, or possibly may conflict, with the interests of the Company, Article 30.7 shall apply only if the conflict arises out of a matter which falls within Article 30.1 or Article 30.2 or has been authorised under section 175(5)(a) of the Act.

Additional steps to be taken by a Director to manage a conflict of interest

- 30.9 Where a Director has an interest which can reasonably be regarded as likely to give rise to a conflict of interest, the Director shall take such additional steps as may be necessary or desirable for the purpose of managing such conflict of interest, including compliance with any procedures laid down from time to time by the Directors for the purpose of managing conflicts of interest generally and/or any specific procedures approved by the Directors for the purpose of or in connection with the situation or matter in question, including without limitation:
  - absenting himself from any discussions, whether in meetings of the Directors or otherwise, at which the relevant situation or matter falls to be considered;
     and
  - (b) excluding himself from documents or information made available to the Directors generally in relation to such situation or matter and/or arranging for such documents or information to be reviewed by a professional adviser to ascertain the extent to which it might be appropriate for him to have access to such documents or information.

Requirement of a Director is to declare an interest

30.10 Subject to section 182 of the Act, a Director shall declare the nature and extent of any interest permitted by Article 30.1 or Article 30.2 at a meeting of the Directors, or by general notice in accordance with section 184 (notice in writing) or section 185 (general notice) of the Act or in such other manner as the Directors may determine, except that no declaration of interest shall be required by a Director in relation to an interest:

- (a) falling under Article 30.1(g);
- (b) if, or to the extent that, the other Directors are already aware of such interest (and for this purpose the other Directors are treated as aware of anything of which they ought reasonably to be aware); or
- (c) if, or to the extent that, it concerns the terms of his service contract (as defined by section 227 of the Act) that have been or are to be considered by a meeting of the Directors, or by a committee of Directors appointed for the purpose under these Articles.

### Shareholder approval

- 30.11 Subject to section 239 of the Act, the Company may by ordinary resolution ratify any contract, transaction or arrangement, or other proposal, not properly authorised by reason of a contravention of any provisions of this Article 30.
- 30.12 For the purposes of this Article 30:
  - (a) a conflict of interest includes a conflict of interest and duty and a conflict of duties;
  - (b) the provisions of section 252 of the Act shall determine whether a person is connected with a Director; and
  - (c) a general notice to the Directors that a Director is to be regarded as having an interest of the nature and extent specified in the notice in any transaction or arrangement in which a specified person or class of persons is interested shall be deemed to be a disclosure that the Director has an interest in any such transaction of the nature and extent so specified.

## 31. NOTICES

- 31.1 Subject to the requirements set out in the Act, any notice given or document sent or supplied to or by any person under these Articles, or otherwise sent by the Company under the Act, may be given, sent or supplied:
  - (a) in hard copy form;
  - (b) in electronic form; or
  - (c) (by the Company) by means of a website (other than notices calling a meeting of Directors),

or partly by one of these means and partly by another of these means.

Notices shall be given and documents supplied in accordance with the procedures set out in the Act, except to the extent that a contrary provision is set out in this Article 31.

Notices in hard copy form

Any notice or other document in hard copy form given or supplied under these Articles may be delivered or sent by first class post (airmail if overseas):

- (a) to the Company or any other company at its registered office; or
- (b) to the address notified to or by the Company for that purpose; or
- (c) in the case of an intended recipient who is a member or his legal personal representative or trustee in bankruptcy, to such member's address as shown in the Company's register of members; or
- (d) in the case of an intended recipient who is a Director or alternate, to his address as shown in the register of Directors; or
- (e) to any other address to which any provision of the Companies Acts (as defined in the Act) authorises the document or information to be sent or supplied; or
- (f) where the Company is the sender, if the Company is unable to obtain an address falling within one of the addresses referred to in (a) to (e) above, to the intended recipient's last address known to the Company.
- Any notice or other document in hard copy form given or supplied under these Articles shall be deemed to have been served and be effective:
  - (a) if delivered, at the time of delivery; or
  - (b) if posted, on receipt or 48 hours after the time it was posted, whichever occurs first.

# Notices in electronic form

- 31.4 Subject to the provisions of the Act, any notice or other document in electronic form given or supplied under these Articles may:
  - if sent by fax or email (provided that a fax number or an address for email has been notified to or by the Company for that purpose), be sent by the relevant form of communication to that address;
  - (b) if delivered or sent by first class post (airmail if overseas) in an electronic form (such as sending a disk by post), be so delivered or sent as if in hard copy form under Article 31.2; or
  - (c) be sent by such other electronic means (as defined in section 1168 of the Act) and to such address(es) as the Company may specify:
    - (i) on its website from time to time; or
    - (ii) by notice (in hard copy or electronic form) to all shareholders of the Company from time to time.
- 31.5 Any notice or other document in electronic form given or supplied under these Articles shall be deemed to have been served and be effective:
  - (a) if sent by facsimile or email (where a fax number or an address for email has been notified to or by the Company for that purpose), on receipt or 48 hours after the time it was sent, whichever occurs first;

- (b) if posted in an electronic form, on receipt or 48 hours after the time it was posted, whichever occurs first;
- (c) if delivered in an electronic form, at the time of delivery; and
- (d) if sent by any other electronic means as referred to in Article 31.4(c), at the time such delivery is deemed to occur under the Act.
- Where the Company is able to show that any notice or other document given or sent under these Articles by electronic means was properly addressed with the electronic address supplied by the intended recipient, the giving or sending of that notice or other document shall be effective notwithstanding any receipt by the Company at any time of notice either that such method of communication has failed or of the intended recipient's non-receipt.

Notice by means of a website

31.7 Subject to the provisions of the Act, any notice or other document or information to be given, sent or supplied by the Company to Shareholders under these Articles may be given, sent or supplied by the Company by making it available on the Company's website.

General

- In the case of joint holders of a share all notices shall be given to the joint holder whose name stands first in the register of members of the Company in respect of the joint holding (the **Primary Holder**). Notice so given shall constitute notice to all the joint holders.
- 31.9 Anything agreed or specified by the Primary Holder in relation to the service, sending or supply of notices, documents or other information shall be treated as the agreement or specification of all the joint holders in their capacity as such (whether for the purposes of the Act or otherwise).

# 32. INDEMNITIES AND INSURANCE

- 32.1 Subject to the provisions of and so far as may be permitted by, the Act:
  - (a) every Director or other officer of the Company (excluding the Auditors) shall be entitled to be indemnified by the Company (and the Company shall also be able to indemnify directors of any associated company (as defined in section 256 of the Act)) out of the Company's assets against all liabilities incurred by him in the actual or purported execution or discharge of his duties or the exercise or purported exercise of his powers or otherwise in relation to or in connection with his duties, powers or office, provided that no Director or any associated company is indemnified by the Company against:
    - (i) any liability incurred by the Director to the Company or any associated company; or
    - (ii) any liability incurred by the Director to pay a fine imposed in criminal proceedings or a sum payable to a regulatory authority by way of a

penalty in respect of non-compliance with any requirements of a regulatory nature; or

- (iii) any liability incurred by the Director:
  - (A) in defending any criminal proceedings in which he is convicted;
  - (B) in defending civil proceedings brought by the Company or any associated company in which final judgment (within the meaning set out in section 234 of the Act) is given against him; or
  - (C) in connection with any application under sections 661(3) or 661(4) or 1157 of the Act (as the case may be) for which the court refuses to grant him relief,

save that, in respect of a provision indemnifying a director of a company (whether or not the Company) that is a trustee of an occupational pension scheme (as that term is used in section 235 of the Act) against liability incurred in connection with that company's activities as trustee of the scheme, the Company shall also be able to indemnify any such Director without the restrictions in Articles 32.1(a)(ii), 32.1(a)(iii)(B) and 32.1(a)(iii)(C) applying;

- (b) the Directors may exercise all the powers of the Company to purchase and maintain insurance for any such Director or other officer against any liability which by virtue of any rule of law would otherwise attach to him in respect of any negligence, default, breach of duty or breach of trust of which he may be guilty in relation to the Company, or any associated company including (if he is a director of a company which is a trustee of an occupational pension scheme) in connection with that company's activities as trustee of an occupational pension scheme.
- The Company shall (at the cost of the Company) effect and maintain for each Director policies of insurance insuring each Director against risks in relation to his office as each director may reasonably specify including without limitation, any liability which by virtue of any rule of law may attach to him in respect of any negligence, default of duty or breach of trust of which he may be guilty in relation to the Company.

## 33. DATA PROTECTION

Each of the Shareholders and Directors consent to the processing of their personal data by the Company, the Shareholders and Directors (each a **Recipient**) for the purpose of due diligence exercises, compliance with applicable laws, regulations and procedures, and the exchange of information among themselves. A Recipient may process the personal data either electronically or manually. The personal data which may be processed under this Article shall include any information which may have a bearing on the prudence or commercial merits of investing in, or disposing of, any shares (or other investment or security) in the Company. Other than as required by law, court order or other regulatory authority, that personal data may not be disclosed by a Recipient or any other person except to a Member of the same

Group (Recipient Group Companies) and to employees, directors and professional advisers of that Recipient or the Recipient Group Companies and funds managed by any of the Recipient Group Companies. Each of the Shareholders and Directors consent to the transfer of relevant personal data to persons acting on behalf of the Recipient and to the offices of any Recipient both within and outside the European Economic Area for the purposes stated above, where it is necessary or desirable to do so.

## 34. SECRETARY

Subject to the provisions of the Act, the Directors may appoint a secretary for such term, at such remuneration and upon such conditions as they may think fit, and any secretary so appointed may be removed by them.

### 35. LIEN

- 35.1 The Company shall have a first and paramount lien (the **Company's Lien**) over every Share (whether or not a fully paid share) for all and any indebtedness of any holder of it to the Company (whether a sole holder or one of two or more joint holders), whether or not that indebtedness or liability is in respect of the Shares concerned and whether or not it is presently payable.
- 35.2 The Company's Lien over a Share:
  - (a) shall take priority over any third party's interest in that Share; and
  - (b) extends to any dividend or other money payable by the Company in respect of that Share and (if the lien is enforced and the Share is sold by the Company) the proceeds of sale of that Share.

The Directors may at any time decide that a Share which is, or would otherwise be, subject to the Company's Lien shall not be subject to it, either wholly or in part.

- 35.3 Subject to the provisions of this Article 35, if:
  - (a) a notice complying with Article 35.4 (A Lien Enforcement Notice:) has been given by the Company in respect of a Share; and
  - (b) the person to whom the notice was given has failed to comply with it, the Company shall be entitled to sell that Share in such manner as the Directors decide.

# 35.4 A Lien Enforcement Notice:

- (a) may only be given by the Company in respect of a Share which is subject to the Company's Lien, in respect of which a sum is payable and the due date for payment of that sum has passed;
- (b) must specify the Share concerned;
- (c) must require payment of the sum payable within 14 days of the notice;
- (d) must be addressed either to the holder of the Share or to a person entitled to it by reason of the holder's death, bankruptcy or otherwise; and

- (e) must state the Company's intention to sell the Share if the notice is not complied with.
- 35.5 Where any Share is sold pursuant to this Article 35:
  - (a) the Directors may authorise any person to execute an instrument of transfer of the Share to the purchaser or a person nominated by the purchaser; and
  - (b) the transferee shall not be bound to see to the application of the consideration, and
  - (c) the transferee's title shall not be affected by any irregularity in or invalidity of the process leading to the sale.
- The net proceeds of any such sale (after payment of the costs of sale and any other costs of enforcing the lien) must be applied:
  - (a) first, in payment of so much of the sum for which the lien exists as was payable at the date of the Lien Enforcement Notice; and
  - (b) secondly, to the person entitled to the Share at the date of the sale, but only after the certificate for the Share sold has been surrendered to the Company for cancellation or an indemnity for lost certificate in a form acceptable to the Board has been given for any lost certificate, and subject to a lien equivalent to the Company's Lien for any money payable (whether or not it is presently payable) as existing upon the Share before the sale in respect of all Shares registered in the name of that person (whether as the sole registered holder or as one of several joint holders) after the date of the Lien Enforcement Notice.
- 35.7 A statutory declaration by a Director or the company secretary that the declarant is a Director or the company secretary and that a Share has been sold to satisfy the Company's Lien on a specified date:
  - (a) shall be conclusive evidence of the facts stated in it as against all persons claiming to be entitled to the Share; and
  - (b) subject to compliance with any other formalities of transfer required by these Articles or by law, shall constitute a good title to the Share.

# 36. CALL NOTICES

36.1 Subject to these Articles and the terms on which Shares are allotted, the Directors may send a notice (a **Call Notice**) to a Shareholder who has not fully paid for that Shareholder's Share(s) requiring the Shareholder to pay the Company a specified sum of money (a **call**) which is payable to the Company by that Shareholder when the Directors decide to send the Call Notice.

# 36.2 A Call Notice:

 (a) may not require a Shareholder to pay a call which exceeds the total sum unpaid on that Shareholder's Shares (whether as to the Share's nominal value or any sum payable to the Company by way of premium);

- (b) shall state when and how any call to which it relates it is to be paid; and
- (c) may permit or require the call to be paid by instalments.
- A Shareholder shall comply with the requirements of a Call Notice, but no Shareholder shall be obliged to pay any call before 14 days have passed since the notice was sent.
- 36.4 Before the Company has received any call due under a Call Notice the Directors may:
  - (a) revoke it wholly or in part; or
  - (b) specify a later time for payment than is specified in the Call Notice, by a further notice in writing to the Shareholder in respect of whose Shares the call is made.
- Liability to pay a call shall not be extinguished or transferred by transferring the Shares in respect of which it is required to be paid. Joint holders of a Share shall be jointly and severally liable to pay all calls in respect of that Share.
- 36.6 Subject to the terms on which Shares are allotted, the Directors may, when issuing Shares, provide that Call Notices sent to the holders of those Shares may require them to:
  - (a) pay calls which are not the same; or
  - (b) pay calls at different times.
- A Call Notice need not be issued in respect of sums which are specified, in the terms on which a Share is issued, as being payable to the Company in respect of that Share (whether in respect of nominal value or premium):
  - (a) on allotment;
  - (b) on the occurrence of a particular event; or
  - (c) on a date fixed by or in accordance with the terms of issue.
- 36.8 If the due date for payment of such a sum as referred to in Article 36.7 has passed and it has not been paid, the holder of the Share concerned shall be treated in all respects as having failed to comply with a Call Notice in respect of that sum, and shall be liable to the same consequences as regards the payment of interest and forfeiture.
- 36.9 If a person is liable to pay a call and fails to do so by the Call Payment Date (as defined below):
  - (a) the Directors may issue a notice of intended forfeiture to that person; and
  - (b) until the call is paid, that person shall be required to pay the Company interest on the call from the Call Payment Date at the Relevant Rate (as defined below).
- 36.10 For the purposes of Article 36.9:

- (a) the Call Payment Date shall be the time when the Call Notice states that a call is payable, unless the Directors give a notice specifying a later date, in which case the Call Payment Date is that later date;
- (b) the Relevant Rate shall be:
  - (i) the rate fixed by the terms on which the Share in respect of which the call is due was allotted;
  - (ii) such other rate as was fixed in the Call Notice which required payment of the call, or has otherwise been determined by the Directors; or
  - (iii) if no rate is fixed in either of these ways, 5 per cent. a year,

provided that the Relevant Rate shall not exceed by more than five percentage points the base lending rate most recently set by the Monetary Policy Committee of the Bank of England in connection with its responsibilities under Part 2 of the Bank of England Act 1998.

- 36.11 The Directors may waive any obligation to pay interest on a call wholly or in part.
- The Directors may accept full payment of any unpaid sum in respect of a Share despite payment not being called under a Call Notice.

#### 37. FORFEITURE OF SHARES

- 37.1 A notice of intended forfeiture:
  - (a) may be sent in respect of any Share for which there is an unpaid sum in respect of which a call has not been paid as required by a Call Notice;
  - (b) shall be sent to the holder of that Share or to a person entitled to it by reason of the holder's death, bankruptcy or otherwise;
  - (c) shall require payment of the call and any accrued interest and all expenses that may have been incurred by the Company by reason of such non-payment by a date which is not fewer than 14 days after the date of the notice;
  - (d) shall state how the payment is to be made; and
  - (e) shall state that if the notice is not complied with, the Shares in respect of which the call is payable will be liable to be forfeited.
- 37.2 If a notice of intended forfeiture is not complied with before the date by which payment of the call is required in the notice of intended forfeiture, then the Directors may decide that any Share in respect of which it was given is forfeited, and the forfeiture is to include all dividends or other moneys payable in respect of the forfeited Shares and not paid before the forfeiture.
- 37.3 Subject to these Articles, the forfeiture of a Share extinguishes:
  - (a) all interests in that Share, and all claims and demands against the Company in respect of it; and

- (b) all other rights and liabilities incidental to the Share as between the person whose Share it was prior to the forfeiture and the Company.
- 37.4 Any Share which is forfeited in accordance with these Articles:
  - (a) shall be deemed to have been forfeited when the Directors decide that it is forfeited:
  - (b) shall be deemed to be the property of the Company; and
  - (c) may be sold, re-allotted or otherwise disposed of as the Directors think fit.
- 37.5 If a person's Shares have been forfeited then:
  - the Company shall send that person notice that forfeiture has occurred and record it in the register of members;
  - (b) that person shall cease to be a Shareholder in respect of those Shares;
  - (c) that person shall surrender the certificate for the Shares forfeited to the Company for cancellation;
  - (d) that person shall remain liable to the Company for all sums payable by that person under the Articles at the date of forfeiture in respect of those Shares, including any interest (whether accrued before or after the date of forfeiture); and
  - (e) the Directors shall be entitled to waive payment of such sums wholly or in part or enforce payment without any allowance for the value of the Shares at the time of forfeiture or for any consideration received on their disposal.
- 37.6 At any time before the Company disposes of a forfeited Share, the Directors shall be entitled to decide to cancel the forfeiture on payment of all calls and interest and expenses due in respect of it and on such other terms as they think fit.
- 37.7 If a forfeited Share is to be disposed of by being transferred, the Company shall be entitled to receive the consideration for the transfer and the Directors shall be entitled to authorise any person to execute the instrument of transfer.
- 37.8 A statutory declaration by a Director or the company secretary that the declarant is a Director or the company secretary and that a Share has been forfeited on a specified date:
  - (a) shall be conclusive evidence of the facts stated in it as against all persons claiming to be entitled to the Share; and
  - (b) subject to compliance with any other formalities of transfer required by the Articles or by law, constitutes a good title to the Share.
- 37.9 A person to whom a forfeited Share is transferred shall not be bound to see to the application of the consideration (if any) nor shall that person's title to the Share be affected by any irregularity in or invalidity of the process leading to the forfeiture or transfer of the Share.

- 37.10 If the Company sells a forfeited Share, the person who held it prior to its forfeiture shall be entitled to receive the proceeds of such sale from the Company, net of any commission, and excluding any sum which:
  - (a) was, or would have become, payable; and
  - (b) had not, when that Share was forfeited, been paid by that person in respect of that Share.

but no interest shall be payable to such a person in respect of such proceeds and the Company shall not be required to account for any money earned on such proceeds.

## 38. SURRENDER OF SHARES

- 38.1 A Shareholder shall be entitled to surrender any Share:
  - (a) in respect of which the Directors issue a notice of intended forfeiture;
  - (b) which the Directors forfeit; or
  - (c) which has been forfeited.

The Directors shall be entitled to accept the surrender of any such Share.

- 38.2 The effect of surrender on a Share shall be the same as the effect of forfeiture on that Share.
- The Company shall be entitled to deal with a Share which has been surrendered in the same way as a Share which has been forfeited.

### 39. AUTHORITY TO CAPITALISE AND APPROPRIATION OF CAPITALISED SUMS

- The Board may, if authorised to do so by an ordinary resolution (with Series B Majority Consent):
  - (a) decide to capitalise any profits of the Company (whether or not they are available for distribution) which are not required for paying a preferential dividend, or any sum standing to the credit of the Company's share premium account or capital redemption reserve; and
  - (b) appropriate any sum which they so decide to capitalise (a Capitalised Sum) to such Shareholders and in such proportions as the Board may in their absolute discretion deem appropriate (the Shareholders Entitled).

Article 36 of the Model Articles shall not apply to the Company.

- 39.2 Capitalised Sums may be applied on behalf of such Shareholders and in such proportions as the Board may (in its absolute discretion) deem appropriate.
- 39.3 Any Capitalised Sum may be applied in paying up new Shares up to the nominal amount (or such amount as is unpaid) equal to the Capitalised Sum, which are then allotted credited as fully paid to the Shareholders Entitled or as they may direct.

- 39.4 A Capitalised Sum which was appropriated from profits available for distribution may be applied in paying up new debentures of the Company which are allotted credited as fully paid to the Shareholders Entitled or as they may direct.
- 39.5 Subject to the Articles the Board may:
  - (a) apply Capitalised Sums in accordance with Articles 39.3 and 39.4 partly in one way and partly another;
  - (b) make such arrangements as they think fit to deal with Shares or debentures becoming distributable in fractions under this Article 39; and
  - (c) authorise any person to enter into an agreement with the Company on behalf of all of the Shareholders Entitled which is binding on them in respect of the allotment of Shares or debentures under this Article 39.

#### 40. SERIES B SHARES

#### Conversion

- 40.1 The Company shall use reasonable endeavours to give at least 10 Business Days' notice in writing to the holders of the Series B Shares of any proposed distribution of assets in accordance with Article 5, and any distribution of Proceeds of Sale in accordance with Article 6, setting out the approximate amount which would be paid per Series B Share and per Ordinary Share on such proposed distribution.
- Any holder of Series B Shares shall be entitled, by notice in writing to the Company, to require conversion into Ordinary Shares of all of the fully paid Series B Shares held by them at any time and those Series B Shares shall convert automatically on the date of such notice (the **Series B Conversion Date**), provided that the holder may in such notice, state that conversion of its Series B Shares into Ordinary Shares is conditional upon the occurrence of one or more events (the **Series B Conditions**).
- 40.3 All of the fully paid Series B Shares shall automatically convert into Ordinary Shares:
  - (a) on the date of receipt by the Company of a written notice given by the Series
     B Majority requiring conversion of the Series B Shares (which date shall be treated as the Series B Conversion Date); or
  - (b) immediately upon the occurrence of a Qualifying IPO.
- In the case of (i) Articles 40.2 and 40.3(a), not more than five Business Days after the Series B Conversion Date; or (ii) in the case of Article 40.3(b), at least five Business Days prior to the occurrence of the Qualifying IPO, each holder of the relevant Series B Shares shall deliver the certificate (or an indemnity for lost certificate in a form acceptable to the Board) in respect of the Series B Shares being converted to the Company at its registered office for the time being.
- Where conversion is mandatory on the occurrence of a Qualifying IPO, that conversion will be effective only immediately prior to and conditional upon such Qualifying IPO (and Series B Conversion Date shall be construed accordingly) and, if such Qualifying IPO does not become effective or does not take place, such

conversion shall be deemed not to have occurred. In the event of a conversion under Article 40.2, if the Series B Conditions have not been satisfied or waived by the relevant holder by the Series B Conversion Date such conversion shall be deemed not to have occurred.

- On the Series B Conversion Date, the relevant Series B Shares shall without further authority than is contained in these Articles stand converted into Ordinary Shares on the basis of one Ordinary Share for each Series B Share held (the **Series B Conversion Ratio**), and the Ordinary Shares resulting from that conversion shall in all other respects rank pari passu with the existing issued Ordinary Shares.
- The Company shall on the Series B Conversion Date enter the holder of the converted Series B Shares on the register of members of the Company as the holder of the appropriate number of Ordinary Shares and, subject to the relevant holder delivering its certificate(s) (or an indemnity for lost certificate in a form acceptable to the Board) in respect of the Series B Shares in accordance with this Article, the Company shall within 10 Business Days of the Series B Conversion Date forward to such holder of Series B Shares by post to his address shown in the register of members, free of charge, a definitive certificate for the appropriate number of fully paid Ordinary Shares.
- 40.8 On the Series B Conversion Date (or as soon afterwards as it is possible to calculate the amount payable), the Company will, if it has sufficient Available Profits, pay to holders of the Series B Shares falling to be converted a dividend equal to all accruals of dividends in relation to those Series B Shares to be calculated on a daily basis down to and including the day immediately preceding the Series B Conversion Date. If the Company has insufficient Available Profits to pay all such accruals of dividends in full then it will pay the same to the extent that it is lawfully able to do so.
- 40.9 The Series B Conversion Ratio shall from time to time be adjusted in accordance with the provisions of this Article:
  - (a) if Series B Shares remain capable of being converted into new Ordinary Shares and there is a consolidation and/or sub-division of Ordinary Shares, the Series B Conversion Ratio shall be adjusted by an amount, which in the opinion of the Board is fair and reasonable, to maintain the right to convert so as to ensure that each Series B Shareholder is in no better or worse position as a result of such consolidation or sub-division, such adjustment to become effective immediately after such consolidation or sub-division;
  - (b) if Series B Shares remain capable of being converted into Ordinary Shares, on an allotment of fully-paid Ordinary Shares pursuant to a capitalisation of profits or reserves to holders of Ordinary Shares the Series B Conversion Ratio shall be adjusted by an amount, which in the opinion of the Board is fair and reasonable, to maintain the right to convert so as to ensure that each Series B Shareholder is in no better or worse position as a result of such capitalisation of profits or reserves, such adjustment to become effective as at the record date for such issue.

- If any Series B Shareholder becomes entitled to fractions of an Ordinary Share as a result of conversion (Series B Fractional Holders), the Directors may (in their absolute discretion) deal with these fractions as they think fit on behalf of the Series B Fractional Holders. In particular, the Directors may aggregate and sell the fractions to a person for the best price reasonably obtainable and distribute the net proceeds of sale in due proportions among the Series B Fractional Holders or may ignore fractions or accrue the benefit of such fractions to the Company rather than the Series B Fractional Holder. For the purposes of completing any such sale of fractions, the chairman of the Company or, failing him, the secretary will be deemed to have been appointed the Series B Fractional Holder's agent for the purpose of the sale.
- 40.11 If a doubt or dispute arises concerning an adjustment of the Series B Conversion Ratio in accordance with Article 40.9, or if so requested by the Series B Majority, the Board shall refer the matter to the Auditors for determination who shall make available to all Shareholders their report and whose certificate as to the amount of the adjustment is, in the absence of manifest error, conclusive and binding on all concerned and their costs shall be met by the Company.

## Anti-Dilution Protection

40.12 If New Securities are issued by the Company at a price per New Security which equates to less than the Series B Price (a Series B Qualifying Issue) (which in the event that the New Security is not issued for cash shall be a price certified by the Auditors acting as experts and not as arbitrators as being in their opinion the current cash value of the new consideration for the allotment of the New Securities) then the Company shall, unless the Series B Majority shall have specifically waived the rights of all of the holders of Series B Shares, as soon as practicable following the Series B Qualifying Issue (or, where such Series B Qualifying Issue forms part of an Investment Round, as soon as practicable following the final closing of such Investment Round) issue to each holder of Series B Qualifying Shares (the Series B Exercising Investor) a number of new Ordinary Shares determined by applying the following formula (and rounding the product, N, down to the nearest whole share), subject to adjustment as certified in accordance with Article 40.14 (the Series B Anti-Dilution Shares):

$$N = \left( \left( \frac{SIP}{WA} \right) \times Z \right) - Z$$

Where

N = Number of Series B Anti-Dilution Shares to be issued to the Series B Exercising Investor

$$WA = \underbrace{(SIPxESC) + (QISPxNS)}_{(ESC + NS)}$$

SIP = Series B Price

ESC = the number of Equity Shares and G Shares in issue plus the aggregate number of Equity Shares and G Shares in respect of which options to subscribe have been granted, or which are subject to convertible securities (including but not limited to warrants) in each case immediately prior to the Series B Qualifying Issue

QISP = the lowest per share price of the New Securities issued pursuant to the Series B Qualifying Issue (which in the event that that New Security is not issued for cash shall be the sum certified by the Auditors acting as experts and not arbitrators as being in their opinion the current cash value of the non-cash consideration for the allotment of the New Security)

NS = the number of New Securities issued pursuant to the Series B Qualifying Issue

Z = the number of Series B Shares held by the Series B Exercising Investor prior to the Series B Qualifying Issue.

## 40.13 The Series B Anti-Dilution Shares shall:

- (a) be paid up by the automatic capitalisation of available reserves of the Company, unless and to the extent that the same shall be impossible or unlawful or a majority of the Series B Exercising Investors shall agree otherwise, in which event the Series B Exercising Investors shall be entitled to subscribe for the Series B Anti-Dilution Shares in cash at par and the entitlement of such Series B Exercising Investors to Series B Anti-Dilution Shares shall be increased by adjustment to the formula set out in Article 40.12 so that the Exercising Investors shall be in no worse position than if they had not so subscribed at par. In the event of any dispute between the Company and any Exercising Investor as to the effect of Article 40.12 or this Article 40.13, the matter shall be referred (at the cost of the Company) to the Auditors for certification of the number of Series B Anti-Dilution Shares to be issued. The Auditors' certification of the matter shall in the absence of manifest error be final and binding on the Company and the Series B Exercising Investor;
- (b) subject to the payment of any cash payable pursuant to Article 40.13(a) (if applicable), be issued, credited fully paid up in cash and shall rank pari passu in all respects with the existing Ordinary Shares, within five Business Days of the expiry of the offer being made by the Company to the Series B Exercising Investor and pursuant to Article 40.13(a).
- In the event of any Bonus Issue or Reorganisation, the Series B Price shall also be subject to adjustment on such basis as may be agreed by the Company with the Series B Majority within 10 Business Days after any Bonus Issue or Reorganisation. If the Company and the Series B Majority cannot agree such adjustment it shall be referred to the Auditors whose determination shall, in the absence of manifest error, be final and binding on the Company and each of the Shareholders. The costs of the Auditors shall be borne by the Company.
- 40.15 For the purposes of Articles 40.12-40.14 any Shares held as Treasury Shares by the Company shall be disregarded when calculating the number of Series B Anti-Dilution Shares to be issued.

## 41. SHARE SALE

- 41.1 Subject to Article 41.2, the completion of any proposed Share Sale (other than a Foundation Share Sale) shall be subject to Series B Majority Consent and Series A Majority Consent. The Directors shall refuse to register any sale or transfer of Shares made pursuant to a Share Sale (other than a Foundation Share Sale) for which Series B Majority Consent and Series A Majority Consent has not been obtained in accordance with this Article 41.
- 41.2 No Series B Majority Consent or Series A Majority Consent will be required pursuant to Article 41.1 in respect of a Share Sale where (i) the proceeds are comprised entirely of cash and/or shares in the purchaser which are listed and freely tradeable without restriction on any internationally recognised exchange; and (ii) the proceeds payable per Share are greater than 150 per cent of the Series B Price.

# 42. IPO

On an IPO, each Shareholder shall:

- (a) to the extent required by the applicable rules of the relevant exchange, retain such number of their Shares held at the time of the IPO for such period after the IPO as is required by the applicable rules of the relevant exchange; and
- (b) have regard to the recommendation of the Company's lead underwriter in determining their respective sale of Shares upon the IPO and shall make such determination with a view to ensuring the success of the IPO provided that, in respect of any IPO on the New York Stock Exchange or NASDAQ, no Shareholder shall be subject to a lock-up period in respect of their Shares that exceeds 6 months.